<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article article-type="research-article" dtd-version="1.2" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">73511</article-id><article-id pub-id-type="doi">10.7554/eLife.73511</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>P2RY14 cAMP signaling regulates Schwann cell precursor self-renewal, proliferation, and nerve tumor initiation in a mouse model of neurofibromatosis</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-251876"><name><surname>Patritti Cram</surname><given-names>Jennifer</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5971-0849</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-254124"><name><surname>Wu</surname><given-names>Jianqiang</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4239-5659</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-254126"><name><surname>Coover</surname><given-names>Robert A</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="pa1">†</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-254128"><name><surname>Rizvi</surname><given-names>Tilat A</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-254129"><name><surname>Chaney</surname><given-names>Katherine E</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-254130"><name><surname>Ravindran</surname><given-names>Ramya</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-254131"><name><surname>Cancelas</surname><given-names>Jose A</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-254132"><name><surname>Spinner</surname><given-names>Robert J</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-210175"><name><surname>Ratner</surname><given-names>Nancy</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5030-9354</contrib-id><email>nancy.ratner@cchmc.org</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01hcyya48</institution-id><institution>Division of Experimental Hematology and Cancer Biology, Cancer &amp; Blood Diseases Institute, Cincinnati Children's Hospital Medical Center</institution></institution-wrap><addr-line><named-content content-type="city">Cincinnati</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01e3m7079</institution-id><institution>Neuroscience Graduate Program, University of Cincinnati College of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Cincinnati</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01e3m7079</institution-id><institution>Department of Pediatrics, University of Cincinnati College of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Cincinnati</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01hcyya48</institution-id><institution>Molecular and Developmental Biology, Cincinnati Children’s Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Cincinnati</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01e3m7079</institution-id><institution>Hoxworth Blood Center, College of Medicine, University of Cincinnati</institution></institution-wrap><addr-line><named-content content-type="city">Cincinnati</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02qp3tb03</institution-id><institution>Department of Neurosurgery, Mayo Clinic</institution></institution-wrap><addr-line><named-content content-type="city">Rochester</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Hahn</surname><given-names>William C</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02jzgtq86</institution-id><institution>Dana-Farber Cancer Institute</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Golemis</surname><given-names>Erica A</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0567t7073</institution-id><institution>Fox Chase Cancer Center</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="present-address" id="pa1"><label>†</label><p>Dept. of Basic Pharmaceutical Sciences, High Point University, High Point, United States</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>21</day><month>03</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>11</volume><elocation-id>e73511</elocation-id><history><date date-type="received" iso-8601-date="2021-09-01"><day>01</day><month>09</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2022-01-19"><day>19</day><month>01</month><year>2022</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2021-09-24"><day>24</day><month>09</month><year>2021</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2021.09.24.461701"/></event></pub-history><permissions><copyright-statement>© 2022, Patritti Cram et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Patritti Cram et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-73511-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-73511-figures-v2.pdf"/><abstract><p>Neurofibromatosis type 1 (NF1) is characterized by nerve tumors called neurofibromas, in which Schwann cells (SCs) show deregulated RAS signaling. NF1 is also implicated in regulation of cAMP. We identified the G-protein-coupled receptor (GPCR) P2ry14 in human neurofibromas, neurofibroma-derived SC precursors (SCPs), mature SCs, and mouse SCPs. Mouse <italic>Nf1-/-</italic> SCP self-renewal was reduced by genetic or pharmacological inhibition of P2ry14. In a mouse model of NF1, genetic deletion of P2ry14 rescued low cAMP signaling, increased mouse survival, delayed neurofibroma initiation, and improved SC Remak bundles. P2ry14 signals via G<sub>i</sub> to increase intracellular cAMP, implicating P2ry14 as a key upstream regulator of cAMP. We found that elevation of cAMP by either blocking the degradation of cAMP or by using a P2ry14 inhibitor diminished <italic>NF1</italic>-/- SCP self-renewal in vitro and neurofibroma SC proliferation in in vivo. These studies identify P2ry14 as a critical regulator of SCP self-renewal, SC proliferation, and neurofibroma initiation.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>neurofibromatosis type 1</kwd><kwd>NF1</kwd><kwd>Schwann cell precursors</kwd><kwd>Schwann cell</kwd><kwd>P2RY14</kwd><kwd>EGFR</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>T32-NS007453</award-id><principal-award-recipient><name><surname>Patritti Cram</surname><given-names>Jennifer</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution>Children's Tumor Foundation Young Investigator Award</institution></institution-wrap></funding-source><award-id>2020-01-006</award-id><principal-award-recipient><name><surname>Patritti Cram</surname><given-names>Jennifer</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>NIH-R01-NS28840</award-id><principal-award-recipient><name><surname>Ratner</surname><given-names>Nancy</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>NIH-R37-NS083580</award-id><principal-award-recipient><name><surname>Ratner</surname><given-names>Nancy</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>In a mouse model of neurofibromatosis type 1, the purinergic receptor P2RY14 is a key regulator of Schwann cell precursor self-renewal and proliferation, of neurofibroma tumor initiation and of mouse survival.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Neurofibromatosis type 1 (NF1) is an autosomal dominant disease that affects up to 1:2000 individuals worldwide (<xref ref-type="bibr" rid="bib30">Kallionpää et al., 2018</xref>). To date, there is no cure for NF1, which is characterized by multiple, variable, clinical manifestations (<xref ref-type="bibr" rid="bib23">Friedman, 1998</xref>; <xref ref-type="bibr" rid="bib59">Tabata et al., 2020</xref>). At least half of the children with NF1 develop plexiform neurofibromas (PNs), which are tumors within peripheral nerves. PN may be present at birth and show most rapid growth during the first decade of a child’s life (<xref ref-type="bibr" rid="bib44">Nguyen et al., 2012</xref>). PNs can occur in any cranial or peripheral nerve and have the potential to transform into lethal malignant peripheral nerve sheath tumors (MPNST) (<xref ref-type="bibr" rid="bib47">Prudner et al., 2020</xref>). Neurofibroma infiltration of normal nerves in NF1 patients results in a complicated risk profile because it can cause nerve damage and compress nearby vital organs (<xref ref-type="bibr" rid="bib33">Kim et al., 2017</xref>). Therefore, understanding how neurofibromas form and how to treat them is under intense investigation.</p><p>Peripheral nerve glial cells, Schwann cells (SCs), are the only cell type in neurofibromas that shows bi-allelic loss-of-function mutations in the <italic>NF1</italic> tumor suppressor gene (<xref ref-type="bibr" rid="bib52">Serra et al., 1997</xref>; <xref ref-type="bibr" rid="bib53">Serra et al., 2001</xref>). Neurofibroma SCs also show aberrant properties ex vivo, consistent with it being the primary pathogenic cell type in neurofibromas (<xref ref-type="bibr" rid="bib54">Sheela et al., 1990</xref>; <xref ref-type="bibr" rid="bib32">Kim et al., 1995</xref>). In mice, neural crest cells develop into SC precursors (SCPs) between embryonic day 11 (E11) and E13 (<xref ref-type="bibr" rid="bib27">Jessen and Mirsky, 2019</xref>). SCPs or related boundary cap cells can serve as cells-of-origin for neurofibromas, as loss of <italic>Nf1</italic> in these cells causes PN formation (<xref ref-type="bibr" rid="bib70">Zhu et al., 2002</xref>; <xref ref-type="bibr" rid="bib65">Wu et al., 2008</xref>; <xref ref-type="bibr" rid="bib10">Chen et al., 2014</xref>; <xref ref-type="bibr" rid="bib11">Chen et al., 2019</xref>).</p><p>In vitro, embryonic SCPs retain multi-lineage differentiation potential and self-renewal capabilities for several passages, indicating that they are progenitor-like cells (<xref ref-type="bibr" rid="bib27">Jessen and Mirsky, 2019</xref>). Mouse SCPs also express epidermal growth factor receptor<sup>+</sup> (EGFR<sup>+</sup>) and respond to EGF with limited self-renewal (<xref ref-type="bibr" rid="bib63">Williams et al., 2008</xref>). EGFR<sup>+</sup> cells that co-express the SC marker S100 account for about 1.8% human neurofibroma cells (<xref ref-type="bibr" rid="bib16">DeClue et al., 2000</xref>). The idea that these cells may be tumor-initiating cells is consistent with the finding that human neurofibromas sorted for co-expression of the SC marker p75<sup>+</sup> and EGFR show limited self-renewal in vitro. Also, EGFR-dependent <italic>Nf1<sup>-/-</sup></italic> SCPs show increased self-renewal and form neurofibromas upon transplantation (<xref ref-type="bibr" rid="bib29">Joseph et al., 2008</xref>; <xref ref-type="bibr" rid="bib63">Williams et al., 2008</xref>). Together, these studies suggest the presence of progenitor-like cells in neurofibromas, which depend on EGFR for self-renewal. EGFR signaling may also play additional roles in transformed SCs, as MPNST cells re-acquire EGFR expression that is absent in mature SC (<xref ref-type="bibr" rid="bib16">DeClue et al., 2000</xref>).</p><p>SCPs differentiate into SCs. When associated with a single large-diameter axonal segment SCs form myelin. SCs associated with multiple smaller diameter axons become non-myelinating Remak cells (<xref ref-type="bibr" rid="bib41">Mirsky et al., 2008</xref>). Neurofibroma SCs show a dramatic change in Remak SC morphology, bundling one or two few axons (<xref ref-type="bibr" rid="bib19">Erlandson and Woodruff, 1982</xref>; <xref ref-type="bibr" rid="bib69">Zheng et al., 2008</xref>), rather than up to 20 small diameter axons in WT nerve Remak bundles (<xref ref-type="bibr" rid="bib24">Harty and Monk, 2017</xref>). Notably, while neurofibromas rarely form, elevation of EGFR in WT SCPs and SCs is sufficient to mimic this nerve disruption phenotype (<xref ref-type="bibr" rid="bib36">Ling et al., 2005</xref>).</p><p>The <italic>NF1</italic> gene encodes neurofibromin, a GTPase activating protein that accelerates the hydrolysis of RAS-GTP to its inactive GDP-bound form downstream of EGFR (<xref ref-type="bibr" rid="bib56">Simanshu et al., 2017</xref>). In SCs, loss of neurofibromin causes increases in GTP-bound RAS (<xref ref-type="bibr" rid="bib32">Kim et al., 1995</xref>; <xref ref-type="bibr" rid="bib55">Sherman et al., 2000</xref>), and RAS-GTP stimulates the mitogen-activated protein kinase (MAPK) pathway and other downstream pathways, including deregulation of the PI3K-AKT signaling (<xref ref-type="bibr" rid="bib15">Dasgupta et al., 2005</xref>; <xref ref-type="bibr" rid="bib28">Johannessen et al., 2008</xref>; <xref ref-type="bibr" rid="bib45">Patmore et al., 2012</xref>; <xref ref-type="bibr" rid="bib31">Keng et al., 2012</xref>). Loss of <italic>NF1</italic> also causes reduced levels of cyclic AMP (cAMP) in <italic>Nf1</italic> mutant mouse, <italic>fly</italic> and zebrafish (<xref ref-type="bibr" rid="bib25">Hegedus et al., 2007</xref>; <xref ref-type="bibr" rid="bib60">Tong et al., 2002</xref>; <xref ref-type="bibr" rid="bib64">Wolman et al., 2014</xref>; <xref ref-type="bibr" rid="bib3">Anastasaki and Gutmann, 2014</xref>). Whether cAMP deregulation occurs downstream of increased RAS-GTP is unclear. Neurofibromin shares homology with the yeast proteins Ira1 and Ira2, which are inhibitory regulators of the RAS-cAMP adenylyl cyclase pathway, but no evidence shows a direct role for NF1 or IRA proteins in direct regulation of cAMP in mammals (<xref ref-type="bibr" rid="bib5">Ballester et al., 1990</xref>; <xref ref-type="bibr" rid="bib39">Martin et al., 1990</xref>; <xref ref-type="bibr" rid="bib67">Xu et al., 1990</xref>). It is unclear how, or if, regulation of cAMP is relevant to neurofibroma initiation or growth but reducing cAMP drove formation of brain tumors in cells lacking <italic>Nf1</italic> (<xref ref-type="bibr" rid="bib62">Warrington et al., 2010</xref>).</p><p>We sought to identify molecules that might affect neurofibroma development in the SC lineage. We identified <italic>P2ry14</italic> as a G-protein-coupled receptor (GPCR) expressed in neurofibroma SCPs. <italic>P2ry14</italic> is activated by extracellular UDP and UDP-sugars and signal through G<sub>i</sub> to inhibit adenylate cyclase (AC), decreasing cAMP (<xref ref-type="bibr" rid="bib2">Abbracchio and Ceruti, 2006</xref>; <xref ref-type="bibr" rid="bib13">Conroy et al., 2016</xref>). Intriguingly, <italic>P2ry14</italic> regulates homeostasis of hematopoietic stem/progenitor cells (<xref ref-type="bibr" rid="bib12">Cho et al., 2014</xref>). Also, satellite glial cells and SCs have been reported to express <italic>P2ry14</italic> in vitro (<xref ref-type="bibr" rid="bib46">Patritti-Cram et al., 2021</xref>). Here, we show that, in vitro, <italic>P2ry14</italic> inhibition decreases mouse SCP self-renewal by modulation of cAMP. In vivo, <italic>P2ry14</italic> knockout increased mouse survival, decreased SC proliferation, improved nerve Remak bundle morphology, and decreased tumor initiation. Pharmacological elevation of cAMP diminished <italic>NF1</italic> deficient SCP self-renewal in vitro and reduced SC proliferation in neurofibroma bearing mice in vivo. We suggest that targeting the <italic>P2ry14</italic> receptor pathway could be relevant for treatment of NF1.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>P2RY14 is expressed in human neurofibroma SCP and promotes SCP self-renewal in vitro</title><p>To characterize SCPs we used flow cytometry. We dissociated cells from human PNs resected for therapeutic purposes from three neurofibroma patients. Cells were sorted into p75<sup>+</sup>/EGFR<sup>-</sup> SCs and p75<sup>+</sup>/EGFR<sup>+</sup> SCP-like tumor-initiating cells. We performed gene expression analysis on these cells and found that <italic>P2ry14</italic> mRNA is elevated in p75<sup>+</sup>/EGFR<sup>+</sup> SCP-like tumor-initiating cells (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Western blot also showed expression in human SCs and neurofibroma SCPs, with 1.9-fold increase of P2ry14 protein in SCP-like cells (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). Anti-<italic>P2ry14</italic> staining also showed <italic>P2ry14</italic> protein membranes of myelinating SCs in human neurofibroma tissue sections (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). To test if <italic>P2ry14</italic><sup>+</sup> SCP-like cells derived from human neurofibromas have altered ability to self-renew, we performed fluorescence-activated cells sorting (FACS) and sorted SCP-like cells into p75<sup>+</sup>/EGFR<sup>+</sup>/<italic>P2ry14</italic><sup>-</sup> and p75<sup>+</sup>/EGFR<sup>+</sup>/<italic>P2ry14</italic><sup>+</sup> cells and plated them at low density to generate unattached spheres in vitro (<xref ref-type="fig" rid="fig1">Figure 1D–F</xref>). Unsorted neurofibroma cells rarely form SCP-like spheres. FACS analysis (of cells from three additional neurofibroma tumors) showed that on average p75<sup>+</sup>/EGFR<sup>+</sup>/<italic>P2ry14</italic><sup>-</sup> cells formed spheres at a frequency of 23.4%, while 64.8% of p75<sup>+</sup>/EGFR<sup>+</sup>/<italic>P2ry14</italic><sup>+</sup> cells formed spheres. The p75<sup>+</sup>/EGFR<sup>+</sup>/<italic>P2ry14 <sup>+</sup></italic> cells maintained their significantly enhanced ability to form spheres in vitro for three passages (<xref ref-type="fig" rid="fig1">Figure 1G and H</xref>). Thus, <italic>P2ry14</italic> is overexpressed in human neurofibroma SCPs in vitro, and marks SCP with the potential to self-renew in vitro.</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>P2RY14 is expressed in human neurofibromas and promotes Schwann cell precursor (SCP) self-renewal in vitro.</title><p>(<bold>A</bold>) Microarray heatmap shows <italic>P2ry14</italic> receptor expression in p75<sup>+</sup>/EGFR<sup>+</sup> SCP-like tumor-initiating cells derived from human plexiform neurofibroma tumor cells compared to p75<sup>+</sup>/EGFR<sup>-</sup> SCP-like cells. (<bold>B</bold>) Western blot of human Schwann cells and neurofibroma SCP shows the latter has a 1.9-fold increase in <italic>P2ry14</italic> protein expression. (<bold>C</bold>) Immunohistochemistry of human neurofibroma shows <italic>P2ry14</italic> expression (DAB staining: brown <italic>[P2ry14</italic> positive cells] blue [cell nuclei]). (<bold>D</bold>) Representative fluorescence-activated cells sorting (FACS) plot shows live sorted human plexiform neurofibroma tumor cells. (<bold>E</bold>) Representative FACS plot shows human plexiform neurofibroma tumor cells sorted into p75<sup>+</sup>/EGFR<sup>+</sup> SCP-like tumor-initiating cells (pink square). (<bold>F</bold>) Representative FACS plot shows p75<sup>+</sup>/EGFR<sup>+</sup> SCP-like tumor-initiating cells further sorted into p75<sup>+</sup>/EGFR<sup>+</sup>/<italic>P2ry14</italic><sup>-</sup> (left, purple square) and P75<sup>+</sup>/EGFR<sup>+</sup>/<italic>P2ry14</italic><sup>+</sup> (right, blue square). (<bold>G</bold>) Photomicrographs of human neurofibromas dissociated using FACS to yield: unsorted, p75<sup>+</sup>/EGFR<sup>+</sup>/<italic>P2ry14</italic><sup>-</sup> and P75<sup>+</sup>/EGFR<sup>+</sup>/<italic>P2ry14</italic><sup>+</sup> cells. (<bold>H</bold>) Quantification of unsorted, p75<sup>+</sup>/EGFR<sup>+</sup>/<italic>P2ry14</italic><sup>-</sup> and P75<sup>+</sup>/EGFR<sup>+</sup>/<italic>P2ry14</italic><sup>+</sup> cells plated in sphere medium. (n = 3; two-way ANOVA; primary: **p = 0.0057, ****p &lt; 0.0001; secondary: *p = 0.0487; **p &lt; 0.0024, ****p &lt; 0.0001; tertiary: *p = 0.0321, ***p = 0.0006).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-73511-fig1-v2.tif"/></fig></sec><sec id="s2-2"><title>Mouse <italic>Nf1</italic> mutant SCPs P2RY14-cAMP signaling regulates self-renewal</title><p>To test if <italic>P2ry14</italic> signaling is relevant in cultured SCP spheres from wild-type (WT) and <italic>Nf1<sup>-/-</sup></italic> mouse embryos, we treated these cells with the highly selective <italic>P2ry14</italic> inhibitor PPTN (4-[4-(4-piperidinyl)phenyl]-7-[4-(trifluoromethyl)phenyl]-2-naphthalenecarboxylic acid) hydrochloride (<xref ref-type="bibr" rid="bib48">Robichaud et al., 2011</xref>). We found that treatment with PPTN reduced the percentage of <italic>Nf1<sup>-/-</sup></italic> mouse SCPs that formed spheres, but had little effect on WT SCPs, consistent with a role in <italic>Nf1</italic> mutant SCP self-renewal (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Photographs of spheres are shown in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>; this experiment was repeated in three biological replicates with similar results. Dose-response analysis confirmed that the optimal concentration of the <italic>P2ry14</italic> inhibitor (PPTN) is 300 nM; as 500 nM PPTN was toxic (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A–F</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Mouse <italic>Nf1</italic> mutant Schwann cell precursors (SCPs) use P2RY14 signaling to regulate self-renewal.</title><p>(<bold>A</bold>) Quantification of percent of sphere forming cells in mouse wild-type (WT) and <italic>Nf1<sup>-/-</sup></italic> SCPs treated with the selective <italic>P2ry14</italic> inhibitor (300 nM 4-[4-(4-piperidinyl)phenyl]-7-[4-(trifluoromethyl)phenyl]-2-naphthalenecarboxylic acid [PPTN]) (primary, secondary, tertiary passage) (n = 3; two-way ANOVA; primary: *p = 0.0375, ***p = 0.0001, ****p &lt; 0.0001; secondary: *p = 0.0101, **p = 0.0015, ***p = 0.0009; tertiary: *p = 0.0101, **p = 0.0050, ***p = 0.0005). (<bold>B</bold>) <italic>P2ry14</italic> mRNA expression in WT and <italic>Nf1<sup>-/-</sup></italic> E12.5 mouse SCP treated with sh non-target (shNT) control and sh<italic>P2ry14</italic> (****p &lt; 0.0001). (<bold>C</bold>) Western blot of WT and <italic>Nf1<sup>-/-</sup></italic> SCPs treated with shNT and sh<italic>P2ry14</italic> showing <italic>P2ry14</italic> knockdown. WT sh<italic>P2ry14</italic> show a 0.4-fold decrease of <italic>P2ry14</italic> protein compared to WT shNT. <italic>Nf1<sup>-/-</sup></italic> sh<italic>P2ry14</italic> show a 0.5-fold decrease compared to <italic>Nf1<sup>-/-</sup></italic>. (<bold>D</bold>) Quantification of percent of sphere forming cells in mouse WT and <italic>Nf1<sup>-/-</sup></italic> SCPs treated with shNT and sh<italic>P2ry14</italic> (n = 3; two-way ANOVA; primary: *p = 0.0288, ****p &lt; 0.0001; secondary: **p = 0.0029,***p = 0.0005, ****p &lt; 0.0001; tertiary: *p = 0.0154, ***p = 0.0007). (<bold>E</bold>) Western blot of WT and <italic>Nf1<sup>-/-</sup></italic> Schwann cell (SC) spheres shows changes in pPKA substrate phosphorylation after sh<italic>P2ry14</italic> knockdown. WT sh<italic>P2ry14</italic> shows a 1.43-fold increase in pPKA after <italic>P2ry14</italic> knockdown. <italic>Nf1-/-</italic> cells have a 1.31-fold increase in pPKA expression after <italic>P2ry14</italic> knockdown. (<bold>F</bold>) Quantification of percent of sphere forming cells in <italic>Nf1<sup>-/-</sup></italic> mouse SCPs treated with 1 µM rolipram or 300 nM PPTN (n = 3; two-way ANOVA; primary: ***p = 0.0002, ****p &lt; 0.0001; secondary **p = 0.0030, ****p &lt; 0.0001; tertiary: *p = 0.0476, ***p = 0.0004).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-73511-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Photomicrographs of three different experiments in which wild-type (WT) and <italic>Nf1<sup>-/-</sup></italic> Schwann cell precursors (SCPs) were treated with 4-[4-(4-piperidinyl)phenyl]-7-[4-(trifluoromethyl)phenyl]-2-naphthalenecarboxylic acid (PPTN), sh<italic>P2ry14</italic> and rolipram.</title><p>(<bold>A</bold>) Photomicrographs of WT and <italic>Nf1<sup>-/-</sup></italic> mouse Schwann cell (SC) spheres treated with the selective <italic>P2ry14</italic> inhibitor (PPTN; 300 nM). (<bold>B</bold>) Photomicrographs of WT and <italic>Nf1<sup>-/-</sup></italic> mouse SC spheres treated with sh non-target (shNT) and sh<italic>P2ry14</italic> (09). (<bold>C</bold>) Photomicrographs of <italic>NF1<sup>-/-</sup></italic> SCPs treated with vehicle and 1 µM of rolipram.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-73511-fig2-figsupp1-v2.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>4-[4-(4-Piperidinyl)phenyl]-7-[4-(trifluoromethyl)phenyl]-2-naphthalenecarboxylic acid (PPTN) dose-response analysis in wild-type (WT) and <italic>Nf1-/-</italic> Schwann cell precursors (SCPs).</title><p>(<bold>A</bold>) Photomicrographs of WT and <italic>Nf1<sup>-/-</sup></italic> mouse Schwann cell (SC) spheres treated with the <italic>P2ry14</italic> inhibitor (PPTN; 30 nM). (<bold>B</bold>) Photomicrographs of WT and <italic>Nf1<sup>-/-</sup></italic> mouse SC spheres treated with the <italic>P2ry14</italic> inhibitor (PPTN; 100 nM). (<bold>C</bold>) Photomicrographs of WT and <italic>Nf1<sup>-/-</sup></italic> mouse SC spheres treated with the <italic>P2ry14</italic> inhibitor (PPTN; 500 nM). (Note: for <bold>A-C</bold>, the same WT and <italic>Nf1<sup>-/-</sup></italic> vehicle controls photomicrographs are used for each dose). (<bold>D</bold>) Quantification of the percent of sphere forming cells after treatment with the <italic>P2ry14</italic> inhibitor (PPTN; 30 nM) in WT and <italic>Nf1<sup>-/-</sup></italic> mouse SC spheres (two-way ANOVA: primary and secondary passage: ****p &lt; 0.0001, tertiary passage: *p = 0.0168, **p = 0.0074). (<bold>E</bold>) Quantification of percent sphere forming cells after treatment with the <italic>P2ry14</italic> inhibitor (PPTN; 100 nM) in WT and <italic>Nf1<sup>-/-</sup></italic> mouse SCP (two-way ANOVA: primary, secondary, and tertiary passage: ****p &lt; 0.0001). (<bold>F</bold>) Quantification of percent sphere forming cells after treatment with the <italic>P2ry14</italic> inhibitor (PPTN; 500 nM) in WT and <italic>Nf1<sup>-/-</sup></italic> mouse SCP; results show that this concentration was toxic to the cells (two-way ANOVA: primary, secondary, and tertiary passage: ****p &lt; 0.0001).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-73511-fig2-figsupp2-v2.tif"/></fig><fig id="fig2s3" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 3.</label><caption><title>Photomicrographs and quantification analysis of two biological replicates of sh<italic>P2ry14</italic> in wild-type (WT) and <italic>Nf1<sup>-/-</sup></italic> Schwann cell precursors (SCPs).</title><p>(<bold>A</bold>) Photomicrographs of WT and <italic>Nf1<sup>-/-</sup></italic> SCP treated with sh<italic>P2ry14</italic> (64). (<bold>B</bold>) Quantification of the percent of sphere forming cells in WT and <italic>Nf1<sup>-/-</sup></italic> SCP after treatment with sh<italic>P2ry14</italic> (64) (n = 3; two-way ANOVA: primary: *p = 0.0184, ****p &lt; 0.0001; secondary: *p = 0.0270, **p = 0.0024; tertiary: *p = 0.0270, **p = 0.0078). (<bold>C</bold>) Photomicrographs of WT and <italic>Nf1<sup>-/-</sup></italic> SCP treated with sh<italic>P2ry14</italic> (84). (<bold>D</bold>) Quantification of the percent of sphere forming cells in WT and <italic>Nf1<sup>-/-</sup></italic> SCP after treatment with sh<italic>P2ry14</italic> (84) (n = 3; two-way ANOVA: primary: ***p = 0.0005, ****p &lt; 0.0001; secondary: *p = 0.0358; tertiary: *p = 0.0245, **p = 0.0030). (Note: for <bold>A</bold> &amp; <bold>C</bold>, the same WT and <italic>Nf1<sup>-/-</sup></italic> sh non-target (shNT) control photomicrographs are used). (<bold>E</bold>) WT and <italic>Nf1<sup>-/-</sup></italic> E12.5 mouse Schwann cells (SCs) cyclic AMP (cAMP) levels measured at baseline and after activation of adenylate cyclase (AC) via forskolin stimulation (n = 3, multiple t-test: vehicle *p = 0.0407, forskolin (5 µM) *p = 0.0045).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-73511-fig2-figsupp3-v2.tif"/></fig></fig-group><p>To confirm these results, we silenced <italic>P2ry14</italic> gene expression using short-hairpin RNAs (shRNAs) targeting <italic>P2ry14</italic>. WT and <italic>Nf1<sup>-/-</sup></italic> mouse SCPs were treated with non-target control (shNT) or shRNA <italic>P2ry14</italic> (sh<italic>P2ry14</italic>). sh<italic>P2ry14</italic> treated cells showed reduced <italic>P2ry14</italic> mRNA (<xref ref-type="fig" rid="fig2">Figure 2B</xref>) and P2ry14 protein (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). Sphere formation was significantly decreased in <italic>Nf1<sup>-/-</sup></italic> SCPs but not WT treated with <italic>P2ry14</italic> shRNA, and this phenotype also persisted for three passages (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). Photomicrographs are shown for one shRNA (sh09) (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>); but the experiment was repeated with two additional <italic>P2ry14</italic> shRNAs in three biological replicates each, with similar results (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3A-D</xref>). We also analyzed cAMP-dependent protein kinase (PKA) substrate phosphorylation (using anti-p-PKA substrate antibody) as an indirect read out of cAMP levels in cells. p-PKA substrate phosphorylation increased in WT and <italic>Nf1<sup>-/-</sup></italic> SCPs sh<italic>P2ry14</italic> treated cells. Importantly, in <italic>Nf1<sup>-/-</sup></italic> SCPs knockdown of <italic>P2ry14</italic> increased levels of pPKA to those in WT shNT levels (<xref ref-type="fig" rid="fig2">Figure 2E</xref>). Thus, PPTN or shRNA targeting P2ry14 affects <italic>Nf1</italic> mutant SCP spheres more than WT spheres, a differential effect consistent with deregulated cell signaling in Nf1 mutant cells.</p><p>To understand if <italic>P2ry14</italic>-mediated changes in cAMP signaling affect SCP self-renewal, we treated WT and <italic>Nf1<sup>-/-</sup></italic> SCPs with the specific phosphodiesterase-4 (PDE4) inhibitor, rolipram. Rolipram blocks degradation of cAMP by PDE4, increasing intracellular levels of cAMP (<xref ref-type="bibr" rid="bib37">Mackenzie and Houslay, 2000</xref>). Treatment with 1 µM rolipram or 300 nM of the <italic>P2ry14</italic> inhibitor (PPTN) decreased <italic>Nf1<sup>-/-</sup></italic> SCP self-renewal; the combination showed additional effect, largely at early passage (<xref ref-type="fig" rid="fig2">Figure 2F</xref>). Photographs of these experiments are shown in (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C</xref>). These results support the idea that the elevated self-renewal in <italic>Nf1<sup>-/-</sup></italic> SCP is due, at least in part, to P2ry14 G<sub>i</sub>-mediated changes in cAMP.</p></sec><sec id="s2-3"><title>P2RY14 is expressed in vivo in mouse SCPs and SCs</title><p>In the <italic>Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup></italic> neurofibroma mouse model, Cre recombinase is expressed from Desert Hedgehog (Dhh) regulatory sequences to effect recombination of the <italic>Nf1<sup>fl/fl</sup></italic> allele, resulting in loss of both <italic>Nf1</italic> alleles in developing SCPs at E12.5 (<xref ref-type="bibr" rid="bib65">Wu et al., 2008</xref>). <italic>Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup></italic> mice develop paraspinal neurofibromas that have loss of axon-SC interaction in Remak bundles, mast cell and macrophage accumulation, and nerve fibrosis, all characteristics of human PNs (<xref ref-type="bibr" rid="bib65">Wu et al., 2008</xref>; <xref ref-type="bibr" rid="bib35">Liao et al., 2018</xref>; <xref ref-type="bibr" rid="bib21">Fletcher et al., 2019a</xref>; <xref ref-type="bibr" rid="bib22">Fletcher et al., 2019b</xref>). In this setting, PNs are present by 4 months of age, and neurofibromas enlarge as the mice age, ultimately compressing the spinal cord causing paralysis and thus, necessitating sacrifice (<xref ref-type="bibr" rid="bib65">Wu et al., 2008</xref>).</p><p>We bred <italic>P2ry14<sup>-/-</sup></italic> mice (<xref ref-type="bibr" rid="bib40">Meister et al., 2014</xref>) and generated <italic>P2ry14</italic><bold><italic><sup>-/-</sup></italic></bold><italic>; Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup>, P2ry14</italic><bold><italic><sup>+/-</sup></italic></bold><italic>; Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup></italic> littermates, and <italic>Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup></italic> controls (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). Genotyping and western blotting verified reduced P2ry14 in <italic>P2ry14<sup>-/-</sup>; Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup></italic> sciatic nerve and neurofibroma tumors compared to <italic>Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup></italic> controls (<xref ref-type="fig" rid="fig3">Figure 3B and C</xref>). In the <italic>P2ry14<sup>-/-</sup></italic> mice, most of the coding region of <italic>P2RY14</italic> is replaced by a β-galactosidase cassette, so that where the <italic>P2ry14</italic> gene is expressed, β-galactosidase is detectable (<xref ref-type="bibr" rid="bib40">Meister et al., 2014</xref>). We visualized <italic>P2ry14</italic> in SOX-10 positive SCPs in the spinal cord dorsal and ventral roots (VR) and in the dorsal root ganglion (DRG) of E12.5 mice (<xref ref-type="fig" rid="fig3">Figure 3D and E</xref>). <italic>P2ry14<sup>-/-</sup>; Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup></italic> SCs in 7-month-old mice were also positive for β-galactosidase staining (<xref ref-type="fig" rid="fig3">Figure 3F</xref>). CNPase (2’,3’ cyclic nucleotide 3’ phosphodiesterase), a known SC marker, co-localized with β-galactosidase staining in the sciatic nerve (<xref ref-type="fig" rid="fig3">Figure 3F</xref><bold>,</bold> inset). <italic>P2ry14</italic> antibody staining confirmed <italic>P2ry14</italic> expression in myelinating SC in mouse WT nerve and in <italic>Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup></italic> neurofibromas (<xref ref-type="fig" rid="fig3">Figure 3G</xref>).</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>P2RY14 is expressed in Schwann cell precursors (SCPs) and Schwann cells (SCs) in vivo in a mouse model of neurofibromatosis.</title><p>(<bold>A</bold>) Schematic of generation of neurofibroma mice breeding of <italic>P2ry14<sup>-/-</sup></italic> mice with <italic>Nf<sup>fl/fl</sup></italic> mice to obtain <italic>P2ry14<sup>+/-</sup>; Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup></italic> and <italic>P2ry14<sup>-/-</sup>; Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup></italic> littermates after several crosses. (<bold>B</bold>) Genotyping confirmation of wild-type (WT) and <italic>P2ry14</italic> knockout (KO) alleles. (<bold>C</bold>) Western blot of sciatic nerve and neurofibroma tumors of <italic>Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup></italic> and <italic>P2ry14<sup>-/-</sup>;Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup></italic> mice show decrease in <italic>P2ry14</italic> expression upon <italic>P2ry14</italic> knockdown (1- to 0.1-fold decrease in sciatic nerve and 1- to 0.2-fold decrease in neurofibroma tissue). (<bold>D</bold>) Spinal cord (SC) immunofluorescent staining of mouse embryos at embryonic day 12.5 (E12.5) shows <italic>P2ry14</italic> expression (β-galactosidase) co-localization with SOX-10 SCs at the dorsal root ganglion (DRG) and ventral roots (VR). (<bold>E</bold>) Spinal cord (SC) immunofluorescent staining of mouse embryos at E12.5 shows <italic>P2ry14</italic> expression (β-galactosidase) co-localization with SOX-10 SCs at DRG. E1 and E2 insets show enlarged sections of the DRG. (<bold>F</bold>) Immunofluorescent staining of 7-month-old mouse sciatic nerve shows β-galactosidase positive staining as a confirmation of <italic>P2ry14</italic> knock-in; co-labeling of β-galactosidase and CNPase shows that <italic>P2ry14</italic> co-localizes with SCs (inset). (<bold>G</bold>) DAB staining of 7-month-old WT nerve and <italic>Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup></italic> mouse neurofibromas (DAB staining: brown [<italic>P2ry14</italic> positive cells] blue [cell nuclei]).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-73511-fig3-v2.tif"/></fig></sec><sec id="s2-4"><title>P2RY14 deletion in mouse model of neurofibroma increases survival, delays neurofibroma initiation, and improves SC Remak bundle disruption</title><p>Kaplan-Meier survival analysis showed that <italic>P2ry14<sup>-/-</sup>; Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup></italic> have a significant survival advantage compared to neurofibroma-bearing mice (<italic>Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup></italic>; p = 0.0256). In fact, <italic>P2ry14<sup>-/-</sup>;Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup></italic> did not differ significantly from non-neurofibroma bearing <italic>Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup></italic> control littermates (p = 0.1367) (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). To test if <italic>P2RY</italic>14 deletion plays a role in neurofibroma initiation, we analyzed <italic>Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup></italic> and <italic>P2ry14 <sup>-/-</sup>;Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup></italic> mice to 4 months of age, when tumor is first detectable. Gross dissection of spinal cords from these mice showed that <italic>P2ry14<sup>-/-</sup>;Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup></italic> have decreased neurofibroma number, consistent with a role in tumor initiation, and only slightly reduced neurofibroma diameter (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A–C</xref>). Ki67 and H&amp;E staining of neurofibromas in these 4-month-old mice showed no evident changes between genotypes in cell proliferation or cell morphology (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1D–F</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>P2RY14 deletion in a mouse model of neurofibroma increases survival and delays neurofibroma initiation.</title><p>(<bold>A</bold>) Kaplan-Meier survival plot of <italic>Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup></italic> (red line; n = 8); <italic>P2ry14<sup>+/-</sup>; Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup></italic> (black line, n = 14); <italic>P2ry14<sup>-/-</sup>; Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup></italic> (blue line; n = 13); <italic>Nf1<sup>fl/+</sup></italic> control (green line, n = 11) (*p = 0.0256) shows <italic>P2ry14<sup>-/-</sup>;Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup></italic> have increased survival. (<bold>B</bold>) Representative image of gross dissection of <italic>Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup></italic> and <italic>P2ry14<sup>-/-</sup>;Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup></italic> mice at 7 months of age. (<bold>C</bold>) Neurofibroma tumor number quantification at 7 months of age (unpaired t-test ****p &lt; 0.0001). (<bold>D</bold>) Neurofibroma diameter quantification at 7 months (unpaired t-test ***p = 0.0004) (for <bold>C</bold> and <bold>D</bold>: <italic>Nf1<sup>fl/fl</sup>;Dhh<sup>+</sup></italic> n = 8 mice, 48 neurofibroma tumors; <italic>P2ry14-/-;Nf1<sup>fl/fl</sup>;Dhh+</italic> n = 8 mice, 11 neurofibroma tumors). (<bold>E</bold>) Ki67 staining of mouse dorsal root ganglion (DRG) and neurofibroma tumor tissue at 7 months of age. (<bold>F</bold>) Quantification of Ki67+ cells in mouse DRG and neurofibroma tumor tissue at 7 months of age (one-way ANOVA; multiple comparisons ***p = 0.0008; ****p &lt; 0.0001). (<bold>G</bold>) Anti-p-PKA substrate staining in wild-type (WT), <italic>Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup></italic> and <italic>P2ry14<sup>-/-</sup>; Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup></italic> mice. p-PKA substrate phosphorylation labeling co-localized with CNPase Schwann cell (SC) marker (insets).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-73511-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Tumor dissection of Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup> and P2ry14<sup>-/-</sup>;Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup> mice at 4 months and immunostaining analysis of 4- and 7-month sciatic nerve and tumors.</title><p>(<bold>A</bold>) Representative image of gross dissection of Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup> and P2ry14<sup>-/-</sup>;Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup> mice at 4 months. (<bold>B</bold>) Neurofibroma tumor number quantification at 4 months of age (unpaired t-test **p=0.0052). (<bold>C</bold>) Neurofibroma tumor diameter quantification at 4 months (unpaired t-test **p=0.0489) (for figures <bold>B and C</bold>: Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup> n=5 mice, 19 neurofibroma tumors; P2ry14<sup>-/-</sup>;Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup> n=5 mice; 5 neurofibroma tumors). (<bold>D</bold>) Ki67+ staining of Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup> and P2ry14<sup>-/-</sup>;Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup> neurofibromas at 4 months of age. (<bold>E</bold>) Quantification of percent of Ki67 positive cells in Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup> and P2ry14<sup>-/-</sup>;Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup> 4-month-old mice (t-test; n.s.). (<bold>F</bold>) H&amp;E staining at 4 months in Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup> and P2ry14<sup>-/-</sup>; Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup> mice. (<bold>G</bold>) Ki67 immunofluorescence co-labeling with CNPase (Schwann cell [SC] marker) in 7-month sciatic nerve. (<bold>H</bold>) H&amp;E tumor staining at 7 months in Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup> and P2ry14<sup>-/-</sup>;Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup> mice.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-73511-fig4-figsupp1-v2.tif"/></fig></fig-group><p>To determine if the effects of <italic>P2ry14</italic> differ over time, we aged <italic>Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup></italic> and <italic>P2ry14<sup>-/-</sup>;Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup></italic> mice. At 7 months <italic>P2ry14<sup>-/-</sup>;Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup></italic> mice also showed significantly fewer neurofibromas compressing the spinal cord on gross dissection (<xref ref-type="fig" rid="fig4">Figure 4B and C</xref>); tumor diameter was reduced to a lesser degree (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). At this age, <italic>P2ry</italic>14 loss decreased Ki67+ cells in neurofibroma tissue sections (<xref ref-type="fig" rid="fig4">Figure 4E–F</xref>); many of these proliferative cells expressed the SC marker CNPase (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1G</xref>). However, H&amp;E staining showed characteristic neurofibroma morphology (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1H</xref>). To determine if cAMP is affected by loss of <italic>P2ry14</italic> in tumors<italic>,</italic> we stained with anti-p-PKA substrate antibody. <italic>Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup></italic> nerves showed a decrease in p-PKA substrate phosphorylation versus WT mice. Remarkably, this decrease was reversed in <italic>P2ry14<sup>-/-</sup>;Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup></italic> nerves (<xref ref-type="fig" rid="fig4">Figure 4G</xref>). pPKA labeling co-localized with CNPase, suggesting that the changes in p-PKA substrate phosphorylation expression are at least in part, in nerve SCs (<xref ref-type="fig" rid="fig4">Figure 4G</xref>, insets). Based on these results, we conclude that <italic>P2ry</italic>14 deletion in vivo in neurofibroma mice increases mouse survival and delays neurofibroma initiation and has lesser effects on SC proliferation.</p><p>We also examined the effects of <italic>P2ry</italic>14 loss on nerve disruption phenotype using electron microscopy. At 4 months, <italic>Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup></italic> nerves already show disrupted Remak bundles (reduced numbers of axons ensheathed by individual SCs); this phenotype was rescued in <italic>P2ry14<sup>-/-</sup>;Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup></italic> mice (<xref ref-type="fig" rid="fig5">Figure 5A and C</xref>). By 7 months, <italic>Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup></italic> nerves were even more severely disrupted, and rescued to near WT levels by <italic>P2ry14</italic> loss (<xref ref-type="fig" rid="fig5">Figure 5B and D</xref>). We conclude that genetic knockout of <italic>P2ry14</italic> in neurofibroma-bearing mice improves the Remak bundle defects characteristic of neurofibroma-bearing mice, and that are present in both nerve and neurofibroma.</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>P2RY14 deletion improves nerve ultrastructure.</title><p>(<bold>A</bold>) Electron micrograph of saphenous nerve of 4-month-old wild-type (WT)<italic>, Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup>, P2ry14<sup>-/-</sup>; Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup></italic> and <italic>P2ry14<sup>-/-</sup></italic> mice. (<bold>B</bold>) Electron micrograph of saphenous nerve of 7-month-old WT<italic>, Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup></italic> and <italic>P2ry14<sup>-/-</sup>;Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup></italic> mice. (<bold>C</bold>) Remak bundle quantification at 4 months of age (n = 3; two-way ANOVA: ****p &lt; 0.0001). (<bold>D</bold>) Remak bundle quantification at 7 months of age (n = 3; two-way ANOVA: **p = 0.0027, ****p &lt; 0.0001).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-73511-fig5-v2.tif"/></fig></sec><sec id="s2-5"><title>Increasing cAMP in neurofibroma-bearing mice by rolipram or a P2RY14 inhibitor decreases SC proliferation in neurofibromas</title><p>Results presented above indicate that loss of <italic>P2ry14</italic> during embryonic development delays phenotypes caused by <italic>Nf1</italic> loss in SCP and SCs. To test if <italic>P2ry14</italic> signaling might also play roles in tumor maintenance, we took pharmacological approaches. We treated <italic>Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup></italic> mice with vehicle or 5 mg/kg rolipram for 60 days to test if cell proliferation in established <italic>Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup></italic> neurofibromas is affected by increasing cAMP levels (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). All mice survived rolipram treatment without significant weight loss. Neurofibroma lysates from rolipram treated mice confirmed increases in p-PKA substrate phosphorylation (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). Numbers of mice assessed did not allow for tumor volume analysis. However, cell proliferation (Ki67 staining) in tissue sections revealed that rolipram treated neurofibromas show significantly decreased cell proliferation in vivo (<xref ref-type="fig" rid="fig6">Figure 6C and D</xref>).</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Cyclic AMP (cAMP) increase in a mouse model of neurofibromatosis either by rolipram or P2RY14 inhibitor treatment decreases Schwann cell (SC) proliferation.</title><p>(<bold>A</bold>) Rolipram drug treatment experimental design. (<bold>B</bold>) Tumor lysates of vehicle and rolipram treated <italic>Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup></italic> mice show changes in p-PKA substrate. (<bold>C</bold>) Ki67 staining at 9 months of age in vehicle and rolipram treated mice. (<bold>D</bold>) Quantification of Ki67+ cells in vehicle treated versus rolipram treated mice (unpaired t-test: ****p &lt; 0.0001; n = 3). (<bold>E</bold>) <italic>P2ry14</italic> inhibitor (4-[4-(4-piperidinyl)phenyl]-7-[4-(trifluoromethyl)phenyl]-2-naphthalenecarboxylic acid [PPTN]) drug treatment experimental design. (<bold>F</bold>) Immunofluorescent staining of sciatic nerve of 4-month-old wild-type (WT), <italic>Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup></italic> (vehicle) and <italic>Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup></italic> (PPTN treated) shows increased p-PKA expression after PPTN treatment. (<bold>G</bold>) Ki67+ staining of <italic>Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup></italic> (vehicle) and <italic>Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup></italic> (PPTN treated) neurofibroma tissue. (<bold>H</bold>) Quantification of Ki67+ cells after PPTN treatment in neurofibroma tissue.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-73511-fig6-v2.tif"/></fig><p>To test if short-term inhibition of <italic>P2ry14</italic> in <italic>Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup></italic> neurofibroma mice similarly affects pPKA levels and cell proliferation, we treated 4-month-old <italic>Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup></italic> mice with a <italic>P2ry14</italic> inhibitor (PPTN) (<xref ref-type="bibr" rid="bib48">Robichaud et al., 2011</xref>; <xref ref-type="bibr" rid="bib6">Battistone et al., 2020</xref>). Oral bioavailability for this inhibitor is poor, therefore, osmotic minipumps were implanted subcutaneosuly to release a daily dose of 4.55 mg/kg for 14 days as described (<xref ref-type="bibr" rid="bib6">Battistone et al., 2020</xref>). At day 14, mice were sacrificed and tissue harvested (<xref ref-type="fig" rid="fig6">Figure 6E</xref>). Immunostaining showed the expected increase in pPKA-substrate staining in the sciatic nerve of <italic>Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup></italic> mice after PPTN treatment (<xref ref-type="fig" rid="fig6">Figure 6F</xref>). Short-term treatment with the <italic>P2ry14</italic> inhibitor also decreased cell proliferation (Ki67+ cells) in neurofibroma tissue sections PPTN treated mice (<xref ref-type="fig" rid="fig6">Figure 6G and H</xref>). These results suggest that <italic>P2ry14</italic> and cAMP play at least a partial role in tumor maintenance. Altogether, these in vitro and in vivo studies show that in a mouse model of neurofibromatosis, <italic>P2ry14</italic> is a key regulator of SCP self-renewal, SC proliferation, neurofibroma initiation, and neurofibroma maintenance.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>GPCR-mediated regulation of cAMP occurs upon <italic>NF1</italic> loss in mammals (<xref ref-type="bibr" rid="bib14">Dasgupta et al., 2003</xref>; <xref ref-type="bibr" rid="bib17">Deraredj Nadim et al., 2016</xref>), fish, and dropsophila (<xref ref-type="bibr" rid="bib60">Tong et al., 2002</xref>; <xref ref-type="bibr" rid="bib64">Wolman et al., 2014</xref>). In these systems, PACAP receptors and serotonin receptors have been identified as GPCRs that act upstream of NF1 (<xref ref-type="bibr" rid="bib3">Anastasaki and Gutmann, 2014</xref>; <xref ref-type="bibr" rid="bib17">Deraredj Nadim et al., 2016</xref>). However, the potential role of cAMP in neurofibroma remains unclear. Targeting GPCR signaling has been suggested as a potential therapeutic option to treat NF1, so exploring the relevance of this pathway to peripheral nerve tumors is important.</p><p>We found that human neurofibroma-derived SCP-like cells sorted for GPCR <italic>P2ry14</italic> expression have increased self-renewal potential. Adult peripheral nerves do not contain a stem cell population (<xref ref-type="bibr" rid="bib58">Stierli et al., 2018</xref>). Therefore, neurofibroma SCP-like cells may result from persistence of immature cells and/or from de-differentiation of mutant SCs. In either case, neurofibroma also contain cells that also express <italic>P2ry14</italic>. Our findings are entirely consistent with findings that hematopoietic stem/progenitor cells marked by <italic>P2ry14</italic> stimulate self-renewal (<xref ref-type="bibr" rid="bib34">Lee et al., 2003</xref>; <xref ref-type="bibr" rid="bib12">Cho et al., 2014</xref>; <xref ref-type="bibr" rid="bib26">Holmfeldt et al., 2016</xref>).</p><p>Purinergic receptor <italic>P2ry14</italic> is activated by UDP and by the nucleotide sugars UDP-glucose, UDP-galactose, UDP-glucuronic acid, and UDP-<italic>N</italic>-acetylglucosamine (<xref ref-type="bibr" rid="bib9">Chambers et al., 2000</xref>; <xref ref-type="bibr" rid="bib42">Moore et al., 2003</xref>; <xref ref-type="bibr" rid="bib1">Abbracchio et al., 2003</xref>; <xref ref-type="bibr" rid="bib8">Carter et al., 2009</xref>; <xref ref-type="bibr" rid="bib13">Conroy et al., 2016</xref>). <italic>NF1</italic> mutant cells may release one or more of these ligands, because SCP self-renewal in serum-free medium was reduced by pharmacological <italic>P2ry14</italic> inhibition, and by shRNA targeting <italic>P2ry14</italic>, in the absence of added UDP or UDP-sugars. The small increase in <italic>P2ry14</italic> protein in mutant cells may contribute to increasing signaling downstream of the GPCR, and/or <italic>Nf1</italic> deficient cells may release more UDP-sugars than WT cells. While it is difficult to measure UDP levels in the extracellular milieu without causing cell damage and concomitant release of UDP-sugars (Lazarowki &amp; Harden, 2015), it will be of interest to measure UDP and UDP-sugars both in the neurofibroma extracellular milieu, and in SCP and SC culture medium.</p><p>UDP, UTP, and other nucleotide sugars including UDP-glucose are present at high levels in tumor cells, and released from cells in tumors and injury sites, where they act as danger signals that trigger inflammatory responses (<xref ref-type="bibr" rid="bib18">Eigenbrodt et al., 1992</xref>; <xref ref-type="bibr" rid="bib57">Skelton et al., 2003</xref>). We focused on the role of <italic>P2ry14</italic> in SCs and SCPs, because most of the <italic>P2ry14</italic> expression in peripheral nerve neurofibromas is in CNPase<sup>+</sup> myelinating SCs, based on our use of a β-galactosidase reporter and antibody staining. However, <italic>P2ry14</italic> is also expressed in immune cells and in small sensory neurons and larger diameter sensory neurons (<xref ref-type="bibr" rid="bib57">Skelton et al., 2003</xref>; <xref ref-type="bibr" rid="bib43">Müller et al., 2005</xref>; <xref ref-type="bibr" rid="bib49">Scrivens and Dickenson, 2005a</xref>; <xref ref-type="bibr" rid="bib51">Scrivens and Dickenson, 2006</xref>; <xref ref-type="bibr" rid="bib38">Malin and Molliver, 2010</xref>). In our studies, because we used a global knockout, we cannot exclude the idea that some of the observed in vivo effects are SCP-independent. The recent description of a conditional knockout of <italic>P2ry14</italic> should enable additional studies (<xref ref-type="bibr" rid="bib6">Battistone et al., 2020</xref>).</p><p>Whether the decreased levels of cAMP in <italic>NF1</italic> deficient cells requires upstream RAS signaling is unclear (reviewed in <xref ref-type="bibr" rid="bib7">Bergoug et al., 2020</xref>). In <italic>Nf1</italic> mutant neurons, RAS activation of atypical protein kinase C-zeta causes GRK2-driven Gαs/AC inactivation downstream of the PACAP receptor (<xref ref-type="bibr" rid="bib3">Anastasaki and Gutmann, 2014</xref>). In fly, some investigators proposed direct regulation of AC by loss of <italic>Nf1</italic> (<xref ref-type="bibr" rid="bib60">Tong et al., 2002</xref>), but others propose that regulation is indirect (<xref ref-type="bibr" rid="bib61">Walker and Bernards, 2014</xref>). In addition, PKA phosphorylates neurofibromin and inhibits its GAP activity (<xref ref-type="bibr" rid="bib20">Feng et al., 2004</xref>), suggesting potential negative feedback between NF1/RAS and PKA in WT cells. Furthermore, in some cell types, downstream of <italic>P2ry14</italic>/Gi/o, Ca2<sup>+</sup> mobilization can result in release of factors such as IL-18, which could activate RAS indirectly (<xref ref-type="bibr" rid="bib42">Moore et al., 2003</xref>; <xref ref-type="bibr" rid="bib4">Arase et al., 2009</xref>). All these mechanisms are candidates to explore for relevance to <italic>P2ry14</italic> signaling in SCPs and SCs.</p><p>Genetic knockdown of <italic>P2ry14</italic> increased levels of cAMP-dependent protein kinase (PKA)-mediated phosphorylation in SCP in vitro and SC in vivo, and <italic>NF1<sup>-/-</sup></italic> SCPs treated with rolipram to increase cAMP showed decreased SCP self-renewal. In vivo, neurofibroma bearing mice treated with either rolipram or the <italic>P2ry14</italic> inhibitor showed increases in pPKA expression and decreases in SC proliferation after treatment. These results implicate cAMP modulation as a critical <italic>P2ry14</italic> effector in SCs and SCPs.</p><p>Consistent with these findings, in WT cells, <italic>P2ry14</italic>/Gi/o-mediated decreases in cAMP affect chemotaxis hematopoietic of stem/progenitor cells (<xref ref-type="bibr" rid="bib34">Lee et al., 2003</xref>; <xref ref-type="bibr" rid="bib50">Scrivens and Dickenson, 2005b</xref>). Supporting a role for <italic>P2ry14</italic>-G<sub>i</sub>-driven suppression of cAMP levels in SCP/SC, p-PKA substrate staining was reduced in <italic>Nf1</italic> mutant nerves and elevated by additional loss of <italic>P2ry14</italic>. Importantly, increasing cellular cAMP levels with rolipram mimicked the effects of inhibiting <italic>P2ry14</italic>, reducing SCP self-renewal in vitro and SC proliferation in vivo. Our findings in peripheral nerve neurofibromas are entirely consistent with those in NF1 brain tumors. <xref ref-type="bibr" rid="bib62">Warrington et al., 2010</xref>, found that overexpression of <italic>PDE4A1</italic> caused formation of hypercellular lesions with features of NF1-associated glioma, and rolipram inhibited optic glioma growth in an NF1-driven mouse model (<xref ref-type="bibr" rid="bib62">Warrington et al., 2010</xref>). Thus, rolipram treatment may be relevant to multiple NF1 manifestations.</p><p>In conclusion, <italic>P2ry14</italic> cAMP signaling regulates SCP self-renewal and nerve tumor initiation in neurofibromatosis. <italic>P2ry14</italic> is a candidate for therapeutic intervention as a whole-body knockout of this receptor showed no effect on organismal survival or growth (<xref ref-type="bibr" rid="bib68">Xu et al., 2012</xref>; <xref ref-type="bibr" rid="bib40">Meister et al., 2014</xref>). While the <italic>P2ry14</italic> inhibitor (PPTN) has poor PK properties (<xref ref-type="bibr" rid="bib48">Robichaud et al., 2011</xref>), when drug candidates targeting <italic>P2ry14</italic> become available, they may be useful for prevention or treatment of NF1-driven neurofibromas.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Resource availability</title><sec id="s4-1-1"><title>Lead contact</title><p>Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Nancy Ratner, PhD (<ext-link ext-link-type="uri" xlink:href="https://www.cincinnatichildrens.org/bio/r/nancy-ratner">nancy.ratner@cchmc.org</ext-link>).</p></sec><sec id="s4-1-2"><title>Materials availability</title><p>This study did not generate new unique reagents.</p></sec><sec id="s4-1-3"><title>Animals</title><p>We housed mice in a temperature and humidity-controlled vivarium on a 12 hr dark-light cycle with free access to food and water. The animal care and use committee of Cincinnati Children’s Hospital Medical Center approved all animal use. WT C57Bl/6 mice were from Jackson Laboratory and were used at 4 and 7 months of age. The <italic>Nf1<sup>fl/fl</sup>;</italic>DhhCre mouse line has been described previously by <xref ref-type="bibr" rid="bib65">Wu et al., 2008</xref>. We bred <italic>P2ry14<sup>-/-</sup></italic> male mice (<xref ref-type="bibr" rid="bib40">Meister et al., 2014</xref>; Takeda Cambridge Limited) with <italic>Nf1<sup>fl/fl</sup></italic> female mice to obtain the F1 generation <italic>P2ry14<sup>+/-</sup>;Nf1<sup>fl/+</sup></italic>; then, we bred the F1 mice with <italic>Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup></italic> male mice to obtain <italic>P2ry14<sup>+/-</sup>;Nf1<sup>fl/+</sup>;Dhh<sup>Cre</sup>.</italic> Then, we bred <italic>P2ry14<sup>+/-</sup>;Nf1<sup>fl/+</sup>;Dhh<sup>Cre</sup></italic> (males) with <italic>P2ry14<sup>+/-</sup>;Nf1<sup>fl/+</sup>; Dhh<sup>Cre</sup></italic> (females) to obtain <italic>P2ry14<sup>+/-</sup>; Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup></italic> and <italic>P2ry14;Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup>.</italic> We genotyped mice as described by <xref ref-type="bibr" rid="bib40">Meister et al., 2014</xref>. Littermates were used for controls. Mice of both sexes were used for all experiments.</p></sec><sec id="s4-1-4"><title>Human neurofibroma sample collection</title><p>Fresh PNs (n = 6) were obtained after medically mandated surgeries. Mayo Clinic’s IRB approved a Waiver for HIPAA Authorization and Informed Consent. The reasons given for a Waiver were (a) subject identifiers were removed, (b) research is minimal risk, (c) the waiver will not adversely affect the rights and welfare of the subjects, and (d) research could not be practicably carried out without the waiver.</p></sec><sec id="s4-1-5"><title>FACS analysis</title><p>Fresh surgical PN specimens were enzymatically dissociated as described (<xref ref-type="bibr" rid="bib63">Williams et al., 2008</xref>). For cell sorting, we incubated cell suspensions with anti-<italic>P2ry14</italic> receptor antibody (Rabbit, polyclonal, Alomone labs, # APR-018; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2039847">AB_2039847</ext-link>) on ice for 30 min, washed with PBS twice. We then incubated cells with goat-anti-rabbit-APC (Southern Biotech, Cat# 4050-11S; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2795959">AB_2795959</ext-link>), mouse anti-human monoclonal antibodies against p75/NGFR (Becton-Dickinson, Cat# 40-1457) bound to phycoerythrin (PE), and EGFR (Fitzgerald, Acton, MA, Cat# 61R-E109BAF; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10808749">AB_10808749</ext-link>) bound to FITC on ice in PBS/0.2% human serum for 30 min. After washing, we re-suspended cells in PBS/0.2% human serum containing 2 µg/mL 7-aminoactinomycin D (7-AAD) (Invitrogen, Cat# A1310). We carried out isotopic controls with irrelevant mouse IgG1-APC, mouse-IgG1-PE, and mouse-IgG1-FITC in parallel. Cells were FACS-sorted using a four-laser FACSDiva (Becton-Dickinson) to acquire alive SC sub-population (P75+/EGFR+/<italic>P2ry14</italic>+/7-AAD- and P75+/EGFR+/<italic>P2ry14</italic>-/7-AAD-). Three primary human PNs were FACS-sorted independently.</p></sec><sec id="s4-1-6"><title>Western blotting</title><p>Primary antibodies and dilutions were: Anti-Purinergic Receptor <italic>P2ry14</italic> rabbit (extracellular) (1:200, Sigma-Aldrich, Cat#: P0119; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1078921">AB_1078921</ext-link>); GPR105 Polyclonal antibody rabbit (1:200, Thermo Fisher, Cat#: PA5-34087; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2551440">AB_2551440</ext-link>); phospho PKA substrate (RRXS*/T*) (100G7E) rabbit (1:1000, Cell Signaling Technology, Cat#: 9624S; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_331817">AB_331817</ext-link>).</p></sec><sec id="s4-1-7"><title>Sphere culture</title><p>We dissociated DRG from E12.5 embryos with 0.25% Trypsin (Thermo Fisher, Cat# 25200056) for 20 min at 37°C and obtained single-cell suspensions with narrow-bore pipettes and a 40 μm strainer (BD-Falcon), plating the cells in 24-well low attachment plates (Corning). The free-floating cells were cultured in serum-free medium with EGF and FGF as described (<xref ref-type="bibr" rid="bib63">Williams et al., 2008</xref>). For passage, we dissociated spheres with 0.05% Trypsin (Thermo Fisher, Cat# 25300054) at 37°C for 5 min. For shRNA treatment and sphere counts, we plated SCP cells at low density to avoid sphere fusion (1000 cells/well in 24-well plates). In the <italic>P2ry14</italic> drug studies, we treated the cells with <italic>P2ry14</italic> inhibitor: <italic>P2ry14</italic> Antagonist Prodrug 7j hydrochloride (Axon Medchem, Cat# 1958) at concentrations of 30, 100, 300, and 500 nM. Three biological replicates produced similar results. Dose-response analysis confirmed that the optimal concentration of PPTN was 300 nM in this assay. For the shRNA experiments, we treated cells with three different lentiviral particles: shRNA control plasmid DNA (Sigma-Aldrich, Cat# SHC016-1EA), sh<italic>P2ry14</italic>(09) (Sigma-Aldrich, Cat# SHCLNG-NM_133200; TRCN0000328609), sh<italic>P2ry14</italic>(84) (Sigma-Aldrich, Cat# SHCLNG-NM_133200; TRCN0000328684), sh<italic>P2ry14</italic>(64) (Sigma-Aldrich, Cat# SHCLNG-NM_133200; TRCN0000026664) at MOI = 10, 24 hr after plating. For rolipram experiment, we treated cells with 1 µM rolipram (Selleck, Cat# S1430). To passage, we centrifuged sphere cultures, treated with 0.05% Trypsin for 3 min, dissociated and plated at 2 × 104 cells/mL in 50% conditioned and 50% fresh medium. We counted secondary spheres after 14 days. For every cell line three biological replicates with three technical replicates were done. Of the three biological replicates, the best one was reported as a representative (n = 3). Spheres were counted with an inverted phase contrast microscope after 6 days of plating.</p></sec><sec id="s4-1-8"><title>Primary SC culture</title><p>E12.5 primary mouse SCs were isolated from DRG with neuronal contact in N2 medium with nerve growth factor, then removed from neurons and cultured in SC media (DMEM [Thermo Fisher, Cat# 11965118] + 10% FBS [Gemini Bio-Products, Cat# A87G02J] + β-heregulin peptide [R&amp;D Systems, Cat# 396-HB-050] + forskolin [Cayman Chemical, Cat# 11018]) for one to three passages as described (<xref ref-type="bibr" rid="bib32">Kim et al., 1995</xref>).</p></sec><sec id="s4-1-9"><title>Direct cAMP ELISA</title><p>Primary SCs were plated on poly-L-lysine coated six-well plate (~750,000 cells/well) in DMEM + 10% FBS + β-HRG + forskolin. After cells were confluent, cells were starved with serum-free N2 media with N2 supplement and left incubating for 16 hr. Cells were pre-incubated with MEK inhibitor for 2 hr prior to stimulation. Stimulation was carried out for 2 min and cAMP measurement was done according to manufacturer’s protocol (Direct cAMP ELISA kit by Enzo Life Sciences, Cat# ADI-900-066) using the acetylated format. An aliquot prior to cAMP measurements was set aside for protein quantification using the Bio-Rad protein assay kit. For every cell line two biological replicates with three technical replicates were done. Of the two biological replicates the best one was reported as a representative (n = 3 biological replicates, 3 technical replicates).</p></sec><sec id="s4-1-10"><title>Immunostaining</title><p>For frozen sections, OCT was removed by incubation with 1× PBS. We permeabilized cells in ice-cold MeOH for 10 min, followed by incubation in normal donkey serum (Jackson ImmunoResearch, Cat# 017-000-121; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2337258">AB_2337258</ext-link>) and 0.3% Triton-X100 (Sigma-Aldrich, Cat# X100). Ki67 (1:200, Cell Signaling Technologies, Cat# 12202S; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2620142">AB_2620142</ext-link>), anti-CNPAse (1:250, Sigma-Aldrich Millipore, Cat# AB9342; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_569543">AB_569543</ext-link>); β-galactosidase polyclonal antibody (1:1000, Thermo Fisher, Cat#: A-11132; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_221539">AB_221539</ext-link>). All secondary antibodies were donkey anti-Rat/Rabbit/Goat from Jackson ImmunoResearch, reconstituted in 50% glycerol and used at 1:250 dilution. To visualize nuclei, sections were stained with DAPI for 10 min, washed with PBS and mounted in FluoromountG (Electron Microscopy Sciences, Hatfield, PA). Images were acquired with ImageJ Acquisition software using a fluorescence microscope (Axiovert 200M) with 10×/0.4 or 40×/0.6 objectives (Carl Zeiss, Inc), or with NIS-Elements software using confocal microscopy (Nikon).</p></sec><sec id="s4-1-11"><title>Electron microscopy</title><p>Mice were perfusion fixed with 4% paraformaldehyde and 2.5% glutaraldehyde in 0.1 M phosphate buffer at 7.4 pH. Saphenous nerve was dissected out and postfixed overnight, then transferred to 0.175 mol/L cacodylate buffer, osmicated, dehydrated, and embedded in Embed 812 (Ladd Research Industries). Ultrathin sections were stained in uranyl acetate and lead citrate and viewed on a Hitachi H-7600 microscope.</p></sec><sec id="s4-1-12"><title>Mouse dissection and quantification of neurofibroma number and size</title><p>To quantify neurofibroma number and size, we perfused mice and used a Leica dissecting microscope to dissect the spinal cord with attached DRG and nerve roots at the ages of 4 and 7 months, as previously described (<xref ref-type="bibr" rid="bib66">Wu et al., 2016</xref>). A neurofibroma was defined as a mass surrounding the DRG or nerve roots, with a diameter greater than 1 mm, measured perpendicular to DRG/nerve roots. Neurofibroma diameter for each mouse was measured with ImageJ.</p></sec><sec id="s4-1-13"><title>Osmotic pump drug study</title><p>Four-month-old neurofibroma mice <italic>Nf1<sup>fl/fl</sup>;Dhh<sup>Cre</sup></italic> were treated with the <italic>P2ry14</italic> inhibitor (PPTN HCl) (<ext-link ext-link-type="uri" xlink:href="https://www.tocris.com/products/pptn-hydrochloride_4862">TOCRIS: Cat. 4862</ext-link>). Osmotic minipumps were loaded with the <italic>P2ry14</italic> inhibitor drug according to manufacturer’s instructions with PPTN in saline solution (containing DMSO) or with saline containing equivalent amounts of the vehicle control (DMSO). Osmotic minipumps released the inhibitor hourly for 14 days for a daily dose of 4.55 mg/kg. At day 14, mice were perfusion fixed with 4% paraformaldehyde and used a Leica dissecting microscope to dissect the tissue.</p></sec></sec><sec id="s4-2"><title>RT-PCR</title><p>We isolated total RNA from WT and Nf1 spheres treated with sh<italic>P2ry14</italic> using the RNeasy Plus Micro-Kit (QIAGEN, Cat# 74034) and made cDNA using the High-Capacity Reverse Transcription Kit (Thermo Fisher, Cat# 4368813). We conducted RT-PCR as described in <xref ref-type="bibr" rid="bib63">Williams et al., 2008</xref>. Primer sequence: <italic>P2ry14</italic> forward: 5’-<named-content content-type="sequence">AGCAGATCATTCCCGTGTTGT</named-content>-3’. <italic>P2ry14</italic> reverse: 5’-<named-content content-type="sequence">TCTCAAGAACATAGTGGTGGCT</named-content>-3’.</p></sec><sec id="s4-3"><title>Genotyping</title><p>Power SYBR Green PCR Master Mix (Thermo Fisher, Cat# 4368702) was used for genotyping. We genotyped mice as described by <xref ref-type="bibr" rid="bib40">Meister et al., 2014</xref>. Genotyping primers: β-galactosidase sense: 5’-<named-content content-type="sequence">AGAAGGCACATGGCTGAATATCGA</named-content>-3’. <italic>P2ry14</italic> forward: (5’-<named-content content-type="sequence">AGCTGCCGGACGAAGGAGACCCTGCTC</named-content>-3’). <italic>P2ry14</italic> reverse: 5’-<named-content content-type="sequence">GGTTTTGGAAACCTCTAGGTCATTCTG</named-content>- 3’ (<xref ref-type="bibr" rid="bib40">Meister et al., 2014</xref>).</p></sec><sec id="s4-4"><title>Statistics</title><p>Statistical parameters, including the type of tests, number of samples (n), descriptive statistics, and significance are reported in the figures and figure legends. Two-group comparisons used Student’s t-tests. When single agents were tested at different concentration in a single cell type, we used a one-way ANOVA with a Dunnett’s multiple comparisons test. When multiple genotypes were analyzed in a single experiment, we used a two-way ANOVA with multiple comparisons, without matching, and correction with the Holm-Sidak test. Mann-Whitney test was used for comparisons between genotypes for tissue widths and neurofibroma incidence (GraphPad Prism V9). All data unless otherwise stated is represented as average ± SD, and was analyzed in GraphPad Prism 7.</p></sec></sec></body><back><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Formal analysis, Funding acquisition, Investigation, Methodology, Validation, Visualization, Writing - original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Formal analysis, Investigation, Methodology, Validation, Visualization, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Methodology, Validation, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Methodology</p></fn><fn fn-type="con" id="con5"><p>Methodology</p></fn><fn fn-type="con" id="con6"><p>Formal analysis, Methodology</p></fn><fn fn-type="con" id="con7"><p>Formal analysis, Methodology, Visualization, Writing – review and editing</p></fn><fn fn-type="con" id="con8"><p>Resources</p></fn><fn fn-type="con" id="con9"><p>Conceptualization, Formal analysis, Funding acquisition, Resources, Supervision, Visualization, Writing - original draft, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols (#2018-0103 expiration 01-2022) of Cincinnati Children's Hospital. The protocol was approved by the Committee on the Ethics of Animal Experiments of the Cincinnati Children's Hospital.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="pdf" mimetype="application" xlink:href="elife-73511-transrepform1-v2.pdf"/></supplementary-material><supplementary-material id="sdata1"><label>Source data 1.</label><caption><title>Non-annotated original figures.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-73511-data1-v2.zip"/></supplementary-material><supplementary-material id="sdata2"><label>Source data 2.</label><caption><title>Annotated original figures.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-73511-data2-v2.zip"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>The data sets and original figures generated during this study will be available at Synapse Project (<ext-link ext-link-type="uri" xlink:href="https://www.synapse.org/">https://www.synapse.org/</ext-link>).</p><p>The following dataset was generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Patritti Cram</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Understanding the role of purinergic signaling on tumor formation in a mouse model of Nf1</data-title><source>Synapse</source><pub-id pub-id-type="doi">10.7303/syn27752640</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank Takeda Cambridge Limited and Dr Johannes Grosse for providing the P2RYR14 knock-in mouse. For excellent technical assistance, we thank Mark Jackson and Lindsey E Aschbacher-Smith. Funding: JP-C was supported by NIH-T32-NS007453 and a Children’s Tumor Foundation Young Investigator Award. This work was supported by grants NIH-R01-NS28840 and NIH-R37-NS083580 to NR.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abbracchio</surname><given-names>MP</given-names></name><name><surname>Boeynaems</surname><given-names>JM</given-names></name><name><surname>Barnard</surname><given-names>EA</given-names></name><name><surname>Boyer</surname><given-names>JL</given-names></name><name><surname>Kennedy</surname><given-names>C</given-names></name><name><surname>Miras-Portugal</surname><given-names>MT</given-names></name><name><surname>King</surname><given-names>BF</given-names></name><name><surname>Gachet</surname><given-names>C</given-names></name><name><surname>Jacobson</surname><given-names>KA</given-names></name><name><surname>Weisman</surname><given-names>GA</given-names></name><name><surname>Burnstock</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Characterization of the UDP-glucose receptor (re-named here the P2Y14 receptor) adds diversity to the P2Y receptor family</article-title><source>Trends in Pharmacological Sciences</source><volume>24</volume><fpage>52</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1016/S0165-6147(02)00038-X</pub-id><pub-id pub-id-type="pmid">12559763</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abbracchio</surname><given-names>MP</given-names></name><name><surname>Ceruti</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Roles of P2 receptors in glial cells: focus on astrocytes</article-title><source>Purinergic Signalling</source><volume>2</volume><fpage>595</fpage><lpage>604</lpage><pub-id pub-id-type="doi">10.1007/s11302-006-9016-0</pub-id><pub-id pub-id-type="pmid">18404462</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anastasaki</surname><given-names>C</given-names></name><name><surname>Gutmann</surname><given-names>DH</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Neuronal NF1/RAS regulation of cyclic AMP requires atypical PKC activation</article-title><source>Human Molecular Genetics</source><volume>23</volume><fpage>6712</fpage><lpage>6721</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddu389</pub-id><pub-id pub-id-type="pmid">25070947</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arase</surname><given-names>T</given-names></name><name><surname>Uchida</surname><given-names>H</given-names></name><name><surname>Kajitani</surname><given-names>T</given-names></name><name><surname>Ono</surname><given-names>M</given-names></name><name><surname>Tamaki</surname><given-names>K</given-names></name><name><surname>Oda</surname><given-names>H</given-names></name><name><surname>Nishikawa</surname><given-names>S</given-names></name><name><surname>Kagami</surname><given-names>M</given-names></name><name><surname>Nagashima</surname><given-names>T</given-names></name><name><surname>Masuda</surname><given-names>H</given-names></name><name><surname>Asada</surname><given-names>H</given-names></name><name><surname>Yoshimura</surname><given-names>Y</given-names></name><name><surname>Maruyama</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The UDP-glucose receptor P2RY14 triggers innate mucosal immunity in the female reproductive tract by inducing IL-8</article-title><source>Journal of Immunology (Baltimore, Md)</source><volume>182</volume><fpage>7074</fpage><lpage>7084</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0900001</pub-id><pub-id pub-id-type="pmid">19454705</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ballester</surname><given-names>R</given-names></name><name><surname>Marchuk</surname><given-names>D</given-names></name><name><surname>Boguski</surname><given-names>M</given-names></name><name><surname>Saulino</surname><given-names>A</given-names></name><name><surname>Letcher</surname><given-names>R</given-names></name><name><surname>Wigler</surname><given-names>M</given-names></name><name><surname>Collins</surname><given-names>F</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins</article-title><source>Cell</source><volume>63</volume><fpage>851</fpage><lpage>859</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(90)90151-4</pub-id><pub-id pub-id-type="pmid">2121371</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Battistone</surname><given-names>MA</given-names></name><name><surname>Mendelsohn</surname><given-names>AC</given-names></name><name><surname>Spallanzani</surname><given-names>RG</given-names></name><name><surname>Allegretti</surname><given-names>AS</given-names></name><name><surname>Liberman</surname><given-names>RN</given-names></name><name><surname>Sesma</surname><given-names>J</given-names></name><name><surname>Kalim</surname><given-names>S</given-names></name><name><surname>Wall</surname><given-names>SM</given-names></name><name><surname>Bonventre</surname><given-names>JV</given-names></name><name><surname>Lazarowski</surname><given-names>ER</given-names></name><name><surname>Brown</surname><given-names>D</given-names></name><name><surname>Breton</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Proinflammatory P2Y14 receptor inhibition protects against ischemic acute kidney injury in mice</article-title><source>The Journal of Clinical Investigation</source><volume>130</volume><fpage>3734</fpage><lpage>3749</lpage><pub-id pub-id-type="doi">10.1172/JCI134791</pub-id><pub-id pub-id-type="pmid">32287042</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bergoug</surname><given-names>M</given-names></name><name><surname>Doudeau</surname><given-names>M</given-names></name><name><surname>Godin</surname><given-names>F</given-names></name><name><surname>Mosrin</surname><given-names>C</given-names></name><name><surname>Vallée</surname><given-names>B</given-names></name><name><surname>Bénédetti</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Neurofibromin Structure Functions and Regulation</article-title><source>Cells</source><volume>9</volume><fpage>1</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.3390/cells9112365</pub-id><pub-id pub-id-type="pmid">33121128</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carter</surname><given-names>RL</given-names></name><name><surname>Fricks</surname><given-names>IP</given-names></name><name><surname>Barrett</surname><given-names>MO</given-names></name><name><surname>Burianek</surname><given-names>LE</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Ko</surname><given-names>H</given-names></name><name><surname>Das</surname><given-names>A</given-names></name><name><surname>Jacobson</surname><given-names>KA</given-names></name><name><surname>Lazarowski</surname><given-names>ER</given-names></name><name><surname>Harden</surname><given-names>TK</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Quantification of Gi-mediated inhibition of adenylyl cyclase activity reveals that UDP is a potent agonist of the human P2Y14 receptor</article-title><source>Molecular Pharmacology</source><volume>76</volume><fpage>1341</fpage><lpage>1348</lpage><pub-id pub-id-type="doi">10.1124/mol.109.058578</pub-id><pub-id pub-id-type="pmid">19759354</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chambers</surname><given-names>JK</given-names></name><name><surname>Macdonald</surname><given-names>LE</given-names></name><name><surname>Sarau</surname><given-names>HM</given-names></name><name><surname>Ames</surname><given-names>RS</given-names></name><name><surname>Freeman</surname><given-names>K</given-names></name><name><surname>Foley</surname><given-names>JJ</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>McLaughlin</surname><given-names>MM</given-names></name><name><surname>Murdock</surname><given-names>P</given-names></name><name><surname>McMillan</surname><given-names>L</given-names></name><name><surname>Trill</surname><given-names>J</given-names></name><name><surname>Swift</surname><given-names>A</given-names></name><name><surname>Aiyar</surname><given-names>N</given-names></name><name><surname>Taylor</surname><given-names>P</given-names></name><name><surname>Vawter</surname><given-names>L</given-names></name><name><surname>Naheed</surname><given-names>S</given-names></name><name><surname>Szekeres</surname><given-names>P</given-names></name><name><surname>Hervieu</surname><given-names>G</given-names></name><name><surname>Scott</surname><given-names>C</given-names></name><name><surname>Watson</surname><given-names>JM</given-names></name><name><surname>Murphy</surname><given-names>AJ</given-names></name><name><surname>Duzic</surname><given-names>E</given-names></name><name><surname>Klein</surname><given-names>C</given-names></name><name><surname>Bergsma</surname><given-names>DJ</given-names></name><name><surname>Wilson</surname><given-names>S</given-names></name><name><surname>Livi</surname><given-names>GP</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>A G protein-coupled receptor for UDP-glucose</article-title><source>The Journal of Biological Chemistry</source><volume>275</volume><fpage>10767</fpage><lpage>10771</lpage><pub-id pub-id-type="doi">10.1074/jbc.275.15.10767</pub-id><pub-id pub-id-type="pmid">10753868</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Patel</surname><given-names>AJ</given-names></name><name><surname>Liao</surname><given-names>CP</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Le</surname><given-names>LQ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Cells of Origin in the Embryonic Nerve Roots for NF1-Associated Plexiform Neurofibroma</article-title><source>Cancer Cell</source><volume>26</volume><fpage>695</fpage><lpage>706</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2014.09.009</pub-id><pub-id pub-id-type="pmid">25446898</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Mo</surname><given-names>J</given-names></name><name><surname>Brosseau</surname><given-names>JP</given-names></name><name><surname>Shipman</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Liao</surname><given-names>CP</given-names></name><name><surname>Cooper</surname><given-names>JM</given-names></name><name><surname>Allaway</surname><given-names>RJ</given-names></name><name><surname>Gosline</surname><given-names>SJC</given-names></name><name><surname>Guinney</surname><given-names>J</given-names></name><name><surname>Carroll</surname><given-names>TJ</given-names></name><name><surname>Le</surname><given-names>LQ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Spatiotemporal Loss of NF1 in Schwann Cell Lineage Leads to Different Types of Cutaneous Neurofibroma Susceptible to Modification by the Hippo Pathway</article-title><source>Cancer Discovery</source><volume>9</volume><fpage>114</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-18-0151</pub-id><pub-id pub-id-type="pmid">30348677</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>J</given-names></name><name><surname>Yusuf</surname><given-names>R</given-names></name><name><surname>Kook</surname><given-names>S</given-names></name><name><surname>Attar</surname><given-names>E</given-names></name><name><surname>Lee</surname><given-names>D</given-names></name><name><surname>Park</surname><given-names>B</given-names></name><name><surname>Cheng</surname><given-names>T</given-names></name><name><surname>Scadden</surname><given-names>DT</given-names></name><name><surname>Lee</surname><given-names>BC</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Purinergic P2Y14 receptor modulates stress-induced hematopoietic stem/progenitor cell senescence</article-title><source>The Journal of Clinical Investigation</source><volume>124</volume><fpage>3159</fpage><lpage>3171</lpage><pub-id pub-id-type="doi">10.1172/JCI61636</pub-id><pub-id pub-id-type="pmid">24937426</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conroy</surname><given-names>S</given-names></name><name><surname>Kindon</surname><given-names>N</given-names></name><name><surname>Kellam</surname><given-names>B</given-names></name><name><surname>Stocks</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Drug-like Antagonists of P2Y Receptors—From Lead Identification to Drug Development</article-title><source>Journal of Medicinal Chemistry</source><volume>59</volume><fpage>9981</fpage><lpage>10005</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.5b01972</pub-id><pub-id pub-id-type="pmid">27413802</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dasgupta</surname><given-names>B</given-names></name><name><surname>Dugan</surname><given-names>LL</given-names></name><name><surname>Gutmann</surname><given-names>DH</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>The Neurofibromatosis 1 Gene Product Neurofibromin Regulates Pituitary Adenylate Cyclase-Activating Polypeptide-Mediated Signaling in Astrocytes</article-title><source>The Journal of Neuroscience</source><volume>23</volume><fpage>8949</fpage><lpage>8954</lpage><pub-id pub-id-type="pmid">14523097</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dasgupta</surname><given-names>B</given-names></name><name><surname>Yi</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>DY</given-names></name><name><surname>Weber</surname><given-names>JD</given-names></name><name><surname>Gutmann</surname><given-names>DH</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors</article-title><source>Cancer Research</source><volume>65</volume><fpage>2755</fpage><lpage>2760</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-4058</pub-id><pub-id pub-id-type="pmid">15805275</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeClue</surname><given-names>JE</given-names></name><name><surname>Heffelfinger</surname><given-names>S</given-names></name><name><surname>Benvenuto</surname><given-names>G</given-names></name><name><surname>Ling</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Rui</surname><given-names>W</given-names></name><name><surname>Vass</surname><given-names>WC</given-names></name><name><surname>Viskochil</surname><given-names>D</given-names></name><name><surname>Ratner</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Epidermal growth factor receptor expression in neurofibromatosis type 1-related tumors and NF1 animal models</article-title><source>The Journal of Clinical Investigation</source><volume>105</volume><fpage>1233</fpage><lpage>1241</lpage><pub-id pub-id-type="doi">10.1172/JCI7610</pub-id><pub-id pub-id-type="pmid">10791998</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deraredj Nadim</surname><given-names>W</given-names></name><name><surname>Chaumont-Dubel</surname><given-names>S</given-names></name><name><surname>Madouri</surname><given-names>F</given-names></name><name><surname>Cobret</surname><given-names>L</given-names></name><name><surname>De Tauzia</surname><given-names>ML</given-names></name><name><surname>Zajdel</surname><given-names>P</given-names></name><name><surname>Bénédetti</surname><given-names>H</given-names></name><name><surname>Marin</surname><given-names>P</given-names></name><name><surname>Morisset-Lopez</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Physical interaction between neurofibromin and serotonin 5-HT6 receptor promotes receptor constitutive activity</article-title><source>PNAS</source><volume>113</volume><fpage>12310</fpage><lpage>12315</lpage><pub-id pub-id-type="doi">10.1073/pnas.1600914113</pub-id><pub-id pub-id-type="pmid">27791021</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eigenbrodt</surname><given-names>E</given-names></name><name><surname>Reinacher</surname><given-names>M</given-names></name><name><surname>Scheefers-Borchel</surname><given-names>U</given-names></name><name><surname>Scheefers</surname><given-names>H</given-names></name><name><surname>Friis</surname><given-names>R</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Double role for pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumor cells</article-title><source>Critical Reviews in Oncogenesis</source><volume>3</volume><fpage>91</fpage><lpage>115</lpage><pub-id pub-id-type="pmid">1532331</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erlandson</surname><given-names>RA</given-names></name><name><surname>Woodruff</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="1982">1982</year><article-title>Peripheral nerve sheath tumors: an electron microscopic study of 43 cases</article-title><source>Cancer</source><volume>49</volume><fpage>273</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.1002/1097-0142(19820115)49:2&lt;273::aid-cncr2820490213&gt;3.0.co;2-r</pub-id><pub-id pub-id-type="pmid">7053827</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>L</given-names></name><name><surname>Yunoue</surname><given-names>S</given-names></name><name><surname>Tokuo</surname><given-names>H</given-names></name><name><surname>Ozawa</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Patrakitkomjorn</surname><given-names>S</given-names></name><name><surname>Ichimura</surname><given-names>T</given-names></name><name><surname>Saya</surname><given-names>H</given-names></name><name><surname>Araki</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>PKA phosphorylation and 14-3-3 interaction regulate the function of neurofibromatosis type I tumor suppressor, neurofibromin</article-title><source>FEBS Letters</source><volume>557</volume><fpage>275</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.1016/S0014-5793(03)01507-2</pub-id><pub-id pub-id-type="pmid">14741381</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fletcher</surname><given-names>JS</given-names></name><name><surname>Springer</surname><given-names>MG</given-names></name><name><surname>Choi</surname><given-names>K</given-names></name><name><surname>Jousma</surname><given-names>E</given-names></name><name><surname>Rizvi</surname><given-names>TA</given-names></name><name><surname>Dombi</surname><given-names>E</given-names></name><name><surname>Kim</surname><given-names>MO</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Ratner</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2019">2019a</year><article-title>STAT3 inhibition reduces macrophage number and tumor growth in neurofibroma</article-title><source>Oncogene</source><volume>38</volume><fpage>2876</fpage><lpage>2884</lpage><pub-id pub-id-type="doi">10.1038/s41388-018-0600-x</pub-id><pub-id pub-id-type="pmid">30542122</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fletcher</surname><given-names>JS</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Jessen</surname><given-names>WJ</given-names></name><name><surname>Pundavela</surname><given-names>J</given-names></name><name><surname>Miller</surname><given-names>JA</given-names></name><name><surname>Dombi</surname><given-names>E</given-names></name><name><surname>Kim</surname><given-names>MO</given-names></name><name><surname>Rizvi</surname><given-names>TA</given-names></name><name><surname>Chetal</surname><given-names>K</given-names></name><name><surname>Salomonis</surname><given-names>N</given-names></name><name><surname>Ratner</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2019">2019b</year><article-title>Cxcr3-expressing leukocytes are necessary for neurofibroma formation in mice</article-title><source>JCI Insight</source><volume>4</volume><elocation-id>98601</elocation-id><pub-id pub-id-type="doi">10.1172/jci.insight.98601</pub-id><pub-id pub-id-type="pmid">30728335</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>J</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Neurofibromatosis 1</article-title><source>Gene Reviews</source><volume>1</volume><fpage>1993</fpage><lpage>2021</lpage></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harty</surname><given-names>BL</given-names></name><name><surname>Monk</surname><given-names>KR</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Unwrapping the unappreciated: recent progress in Remak Schwann cell biology</article-title><source>Current Opinion in Neurobiology</source><volume>47</volume><fpage>131</fpage><lpage>137</lpage><pub-id pub-id-type="doi">10.1016/j.conb.2017.10.003</pub-id><pub-id pub-id-type="pmid">29096241</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hegedus</surname><given-names>B</given-names></name><name><surname>Dasgupta</surname><given-names>B</given-names></name><name><surname>Shin</surname><given-names>JE</given-names></name><name><surname>Emnett</surname><given-names>RJ</given-names></name><name><surname>Hart-Mahon</surname><given-names>EK</given-names></name><name><surname>Elghazi</surname><given-names>L</given-names></name><name><surname>Bernal-Mizrachi</surname><given-names>E</given-names></name><name><surname>Gutmann</surname><given-names>DH</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Neurofibromatosis-1 regulates neuronal and glial cell differentiation from neuroglial progenitors in vivo by both cAMP- and Ras-dependent mechanisms</article-title><source>Cell Stem Cell</source><volume>1</volume><fpage>443</fpage><lpage>457</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2007.07.008</pub-id><pub-id pub-id-type="pmid">18371380</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holmfeldt</surname><given-names>P</given-names></name><name><surname>Ganuza</surname><given-names>M</given-names></name><name><surname>Marathe</surname><given-names>H</given-names></name><name><surname>He</surname><given-names>B</given-names></name><name><surname>Hall</surname><given-names>T</given-names></name><name><surname>Kang</surname><given-names>G</given-names></name><name><surname>Moen</surname><given-names>J</given-names></name><name><surname>Pardieck</surname><given-names>J</given-names></name><name><surname>Saulsberry</surname><given-names>AC</given-names></name><name><surname>Cico</surname><given-names>A</given-names></name><name><surname>Gaut</surname><given-names>L</given-names></name><name><surname>McGoldrick</surname><given-names>D</given-names></name><name><surname>Finkelstein</surname><given-names>D</given-names></name><name><surname>Tan</surname><given-names>K</given-names></name><name><surname>McKinney-Freeman</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Functional screen identifies regulators of murine hematopoietic stem cell repopulation</article-title><source>The Journal of Experimental Medicine</source><volume>213</volume><fpage>433</fpage><lpage>449</lpage><pub-id pub-id-type="doi">10.1084/jem.20150806</pub-id><pub-id pub-id-type="pmid">26880577</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jessen</surname><given-names>KR</given-names></name><name><surname>Mirsky</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Schwann Cell Precursors; Multipotent Glial Cells in Embryonic Nerves</article-title><source>Frontiers in Molecular Neuroscience</source><volume>12</volume><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.3389/fnmol.2019.00069</pub-id><pub-id pub-id-type="pmid">30971890</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johannessen</surname><given-names>CM</given-names></name><name><surname>Johnson</surname><given-names>BW</given-names></name><name><surname>Williams</surname><given-names>SMG</given-names></name><name><surname>Chan</surname><given-names>AW</given-names></name><name><surname>Reczek</surname><given-names>EE</given-names></name><name><surname>Lynch</surname><given-names>RC</given-names></name><name><surname>Rioth</surname><given-names>MJ</given-names></name><name><surname>McClatchey</surname><given-names>A</given-names></name><name><surname>Ryeom</surname><given-names>S</given-names></name><name><surname>Cichowski</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>TORC1 is essential for NF1-associated malignancies</article-title><source>Current Biology</source><volume>18</volume><fpage>56</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2007.11.066</pub-id><pub-id pub-id-type="pmid">18164202</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joseph</surname><given-names>NM</given-names></name><name><surname>Mosher</surname><given-names>JT</given-names></name><name><surname>Buchstaller</surname><given-names>J</given-names></name><name><surname>Snider</surname><given-names>P</given-names></name><name><surname>McKeever</surname><given-names>PE</given-names></name><name><surname>Lim</surname><given-names>M</given-names></name><name><surname>Conway</surname><given-names>SJ</given-names></name><name><surname>Parada</surname><given-names>LF</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Morrison</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells</article-title><source>Cancer Cell</source><volume>13</volume><fpage>129</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2008.01.003</pub-id><pub-id pub-id-type="pmid">18242513</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kallionpää</surname><given-names>RA</given-names></name><name><surname>Uusitalo</surname><given-names>E</given-names></name><name><surname>Leppävirta</surname><given-names>J</given-names></name><name><surname>Pöyhönen</surname><given-names>M</given-names></name><name><surname>Peltonen</surname><given-names>S</given-names></name><name><surname>Peltonen</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Prevalence of neurofibromatosis type 1 in the Finnish population</article-title><source>Genetics in Medicine</source><volume>20</volume><fpage>1082</fpage><lpage>1086</lpage><pub-id pub-id-type="doi">10.1038/gim.2017.215</pub-id><pub-id pub-id-type="pmid">29215653</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keng</surname><given-names>VW</given-names></name><name><surname>Rahrmann</surname><given-names>EP</given-names></name><name><surname>Watson</surname><given-names>AL</given-names></name><name><surname>Tschida</surname><given-names>BR</given-names></name><name><surname>Moertel</surname><given-names>CL</given-names></name><name><surname>Jessen</surname><given-names>WJ</given-names></name><name><surname>Rizvi</surname><given-names>TA</given-names></name><name><surname>Collins</surname><given-names>MH</given-names></name><name><surname>Ratner</surname><given-names>N</given-names></name><name><surname>Largaespada</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>PTEN and NF1 inactivation in Schwann cells produces a severe phenotype in the peripheral nervous system that promotes the development and malignant progression of peripheral nerve sheath tumors</article-title><source>Cancer Research</source><volume>72</volume><fpage>3405</fpage><lpage>3413</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-11-4092</pub-id><pub-id pub-id-type="pmid">22700876</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>HA</given-names></name><name><surname>Rosenbaum</surname><given-names>T</given-names></name><name><surname>Marchionni</surname><given-names>MA</given-names></name><name><surname>Ratner</surname><given-names>N</given-names></name><name><surname>DeClue</surname><given-names>JE</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Schwann cells from neurofibromin deficient mice exhibit activation of p21ras, inhibition of cell proliferation and morphological changes</article-title><source>Oncogene</source><volume>11</volume><fpage>325</fpage><lpage>335</lpage><pub-id pub-id-type="pmid">7624147</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>A</given-names></name><name><surname>Stewart</surname><given-names>DR</given-names></name><name><surname>Reilly</surname><given-names>KM</given-names></name><name><surname>Viskochil</surname><given-names>D</given-names></name><name><surname>Miettinen</surname><given-names>MM</given-names></name><name><surname>Widemann</surname><given-names>BC</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Malignant Peripheral Nerve Sheath Tumors State of the Science: Leveraging Clinical and Biological Insights into Effective Therapies</article-title><source>Sarcoma</source><volume>2017</volume><elocation-id>7429697</elocation-id><pub-id pub-id-type="doi">10.1155/2017/7429697</pub-id><pub-id pub-id-type="pmid">28592921</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>B-C</given-names></name><name><surname>Cheng</surname><given-names>T</given-names></name><name><surname>Adams</surname><given-names>GB</given-names></name><name><surname>Attar</surname><given-names>EC</given-names></name><name><surname>Miura</surname><given-names>N</given-names></name><name><surname>Lee</surname><given-names>SB</given-names></name><name><surname>Saito</surname><given-names>Y</given-names></name><name><surname>Olszak</surname><given-names>I</given-names></name><name><surname>Dombkowski</surname><given-names>D</given-names></name><name><surname>Olson</surname><given-names>DP</given-names></name><name><surname>Hancock</surname><given-names>J</given-names></name><name><surname>Choi</surname><given-names>PS</given-names></name><name><surname>Haber</surname><given-names>DA</given-names></name><name><surname>Luster</surname><given-names>AD</given-names></name><name><surname>Scadden</surname><given-names>DT</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>P2Y-like receptor, GPR105 (P2Y14), identifies and mediates chemotaxis of bone-marrow hematopoietic stem cells</article-title><source>Genes &amp; Development</source><volume>17</volume><fpage>1592</fpage><lpage>1604</lpage><pub-id pub-id-type="doi">10.1101/gad.1071503</pub-id><pub-id pub-id-type="pmid">12842911</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>C-P</given-names></name><name><surname>Booker</surname><given-names>RC</given-names></name><name><surname>Brosseau</surname><given-names>J-P</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Mo</surname><given-names>J</given-names></name><name><surname>Tchegnon</surname><given-names>E</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Clapp</surname><given-names>DW</given-names></name><name><surname>Le</surname><given-names>LQ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Contributions of inflammation and tumor microenvironment to neurofibroma tumorigenesis</article-title><source>Journal of Clinical Investigation</source><volume>128</volume><fpage>2848</fpage><lpage>2861</lpage><pub-id pub-id-type="doi">10.1172/JCI99424</pub-id><pub-id pub-id-type="pmid">29596064</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ling</surname><given-names>BC</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Miller</surname><given-names>SJ</given-names></name><name><surname>Monk</surname><given-names>KR</given-names></name><name><surname>Shamekh</surname><given-names>R</given-names></name><name><surname>Rizvi</surname><given-names>TA</given-names></name><name><surname>Decourten-Myers</surname><given-names>G</given-names></name><name><surname>Vogel</surname><given-names>KS</given-names></name><name><surname>DeClue</surname><given-names>JE</given-names></name><name><surname>Ratner</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Role for the epidermal growth factor receptor in neurofibromatosis-related peripheral nerve tumorigenesis</article-title><source>Cancer Cell</source><volume>7</volume><fpage>65</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2004.10.016</pub-id><pub-id pub-id-type="pmid">15652750</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mackenzie</surname><given-names>SJ</given-names></name><name><surname>Houslay</surname><given-names>MD</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Action of rolipram on specific PDE4 cAMP phosphodiesterase isoforms and on the phosphorylation of cAMP-response-element-binding protein (CREB) and p38 mitogen-activated protein (MAP) kinase in U937 monocytic cells</article-title><source>Biochemical Journal</source><volume>347</volume><fpage>571</fpage><lpage>578</lpage><pub-id pub-id-type="doi">10.1042/bj3470571</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malin</surname><given-names>SA</given-names></name><name><surname>Molliver</surname><given-names>DC</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Gi- and Gq-coupled ADP (P2Y) receptors act in opposition to modulate nociceptive signaling and inflammatory pain behavior</article-title><source>Molecular Pain</source><volume>6</volume><fpage>6</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1186/1744-8069-6-21</pub-id><pub-id pub-id-type="pmid">20398327</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>GA</given-names></name><name><surname>Viskochil</surname><given-names>D</given-names></name><name><surname>Bollag</surname><given-names>G</given-names></name><name><surname>McCabe</surname><given-names>PC</given-names></name><name><surname>Crosier</surname><given-names>WJ</given-names></name><name><surname>Haubruck</surname><given-names>H</given-names></name><name><surname>Conroy</surname><given-names>L</given-names></name><name><surname>Clark</surname><given-names>R</given-names></name><name><surname>O’Connell</surname><given-names>P</given-names></name><name><surname>Cawthon</surname><given-names>RM</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21</article-title><source>Cell</source><volume>63</volume><fpage>843</fpage><lpage>849</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(90)90150-d</pub-id><pub-id pub-id-type="pmid">2121370</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meister</surname><given-names>J</given-names></name><name><surname>Le Duc</surname><given-names>D</given-names></name><name><surname>Ricken</surname><given-names>A</given-names></name><name><surname>Burkhardt</surname><given-names>R</given-names></name><name><surname>Thiery</surname><given-names>J</given-names></name><name><surname>Pfannkuche</surname><given-names>H</given-names></name><name><surname>Polte</surname><given-names>T</given-names></name><name><surname>Grosse</surname><given-names>J</given-names></name><name><surname>Schöneberg</surname><given-names>T</given-names></name><name><surname>Schulz</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The G protein-coupled receptor P2Y14 influences insulin release and smooth muscle function in mice</article-title><source>The Journal of Biological Chemistry</source><volume>289</volume><fpage>23353</fpage><lpage>23366</lpage><pub-id pub-id-type="doi">10.1074/jbc.M114.580803</pub-id><pub-id pub-id-type="pmid">24993824</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mirsky</surname><given-names>R</given-names></name><name><surname>Woodhoo</surname><given-names>A</given-names></name><name><surname>Parkinson</surname><given-names>DB</given-names></name><name><surname>Arthur-Farraj</surname><given-names>P</given-names></name><name><surname>Bhaskaran</surname><given-names>A</given-names></name><name><surname>Jessen</surname><given-names>KR</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Novel signals controlling embryonic Schwann cell development, myelination and dedifferentiation</article-title><source>Journal of the Peripheral Nervous System</source><volume>13</volume><fpage>122</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1111/j.1529-8027.2008.00168.x</pub-id><pub-id pub-id-type="pmid">18601657</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>DJ</given-names></name><name><surname>Murdock</surname><given-names>PR</given-names></name><name><surname>Watson</surname><given-names>JM</given-names></name><name><surname>Faull</surname><given-names>RLM</given-names></name><name><surname>Waldvogel</surname><given-names>HJ</given-names></name><name><surname>Szekeres</surname><given-names>PG</given-names></name><name><surname>Wilson</surname><given-names>S</given-names></name><name><surname>Freeman</surname><given-names>KB</given-names></name><name><surname>Emson</surname><given-names>PC</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>GPR105, a novel Gi/o-coupled UDP-glucose receptor expressed on brain glia and peripheral immune cells, is regulated by immunologic challenge: possible role in neuroimmune function</article-title><source>Brain Research. Molecular Brain Research</source><volume>118</volume><fpage>10</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1016/s0169-328x(03)00330-9</pub-id><pub-id pub-id-type="pmid">14559350</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Müller</surname><given-names>T</given-names></name><name><surname>Bayer</surname><given-names>H</given-names></name><name><surname>Myrtek</surname><given-names>D</given-names></name><name><surname>Ferrari</surname><given-names>D</given-names></name><name><surname>Sorichter</surname><given-names>S</given-names></name><name><surname>Ziegenhagen</surname><given-names>MW</given-names></name><name><surname>Zissel</surname><given-names>G</given-names></name><name><surname>Virchow</surname><given-names>JC</given-names><suffix>Jr</suffix></name><name><surname>Luttmann</surname><given-names>W</given-names></name><name><surname>Norgauer</surname><given-names>J</given-names></name><name><surname>Di Virgilio</surname><given-names>F</given-names></name><name><surname>Idzko</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>The P2Y14 receptor of airway epithelial cells: coupling to intracellular Ca2+ and IL-8 secretion</article-title><source>American Journal of Respiratory Cell and Molecular Biology</source><volume>33</volume><fpage>601</fpage><lpage>609</lpage><pub-id pub-id-type="doi">10.1165/rcmb.2005-0181OC</pub-id><pub-id pub-id-type="pmid">16109883</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>R</given-names></name><name><surname>Dombi</surname><given-names>E</given-names></name><name><surname>Widemann</surname><given-names>BC</given-names></name><name><surname>Solomon</surname><given-names>J</given-names></name><name><surname>Fuensterer</surname><given-names>C</given-names></name><name><surname>Kluwe</surname><given-names>L</given-names></name><name><surname>Friedman</surname><given-names>JM</given-names></name><name><surname>Mautner</surname><given-names>V-F</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Growth dynamics of plexiform neurofibromas: a retrospective cohort study of 201 patients with neurofibromatosis 1</article-title><source>Orphanet Journal of Rare Diseases</source><volume>7</volume><fpage>7</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1186/1750-1172-7-75</pub-id><pub-id pub-id-type="pmid">23035791</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patmore</surname><given-names>DM</given-names></name><name><surname>Welch</surname><given-names>S</given-names></name><name><surname>Fulkerson</surname><given-names>PC</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Choi</surname><given-names>K</given-names></name><name><surname>Eaves</surname><given-names>D</given-names></name><name><surname>Kordich</surname><given-names>JJ</given-names></name><name><surname>Collins</surname><given-names>MH</given-names></name><name><surname>Cripe</surname><given-names>TP</given-names></name><name><surname>Ratner</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>In vivo regulation of TGFβ by R-Ras2 revealed through loss of the RasGAP protein Nf1</article-title><source>Cancer Research</source><volume>72</volume><fpage>5317</fpage><lpage>5327</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-12-1972</pub-id><pub-id pub-id-type="pmid">22918885</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patritti-Cram</surname><given-names>J</given-names></name><name><surname>Coover</surname><given-names>RA</given-names></name><name><surname>Jankowski</surname><given-names>MP</given-names></name><name><surname>Ratner</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Purinergic signaling in peripheral nervous system glial cells</article-title><source>Glia</source><volume>69</volume><fpage>1837</fpage><lpage>1851</lpage><pub-id pub-id-type="doi">10.1002/glia.23969</pub-id><pub-id pub-id-type="pmid">33507559</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prudner</surname><given-names>BC</given-names></name><name><surname>Ball</surname><given-names>T</given-names></name><name><surname>Rathore</surname><given-names>R</given-names></name><name><surname>Hirbe</surname><given-names>AC</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Diagnosis and management of malignant peripheral nerve sheath tumors: Current practice and future perspectives</article-title><source>Neuro-Oncology Advances</source><volume>2</volume><fpage>i40</fpage><lpage>i49</lpage><pub-id pub-id-type="doi">10.1093/noajnl/vdz047</pub-id><pub-id pub-id-type="pmid">32642731</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robichaud</surname><given-names>J</given-names></name><name><surname>Fournier</surname><given-names>JF</given-names></name><name><surname>Gagné</surname><given-names>S</given-names></name><name><surname>Gauthier</surname><given-names>JY</given-names></name><name><surname>Hamel</surname><given-names>M</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>Hénault</surname><given-names>M</given-names></name><name><surname>Kargman</surname><given-names>S</given-names></name><name><surname>Levesque</surname><given-names>JF</given-names></name><name><surname>Mamane</surname><given-names>Y</given-names></name><name><surname>Mancini</surname><given-names>J</given-names></name><name><surname>Morin</surname><given-names>N</given-names></name><name><surname>Mulrooney</surname><given-names>E</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Black</surname><given-names>WC</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Applying the pro-drug approach to afford highly bioavailable antagonists of P2Y(14</article-title><source>Bioorganic &amp; Medicinal Chemistry Letters</source><volume>21</volume><fpage>4366</fpage><lpage>4368</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2010.12.113</pub-id><pub-id pub-id-type="pmid">21689930</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scrivens</surname><given-names>M</given-names></name><name><surname>Dickenson</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2005">2005a</year><article-title>Pharmacological effects mediated by UDP-glucose that are independent of P2Y14 receptor expression</article-title><source>Pharmacological Research</source><volume>51</volume><fpage>533</fpage><lpage>538</lpage><pub-id pub-id-type="doi">10.1016/j.phrs.2005.02.001</pub-id><pub-id pub-id-type="pmid">15829433</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scrivens</surname><given-names>M</given-names></name><name><surname>Dickenson</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2005">2005b</year><article-title>Functional expression of the P2Y14 receptor in murine T-lymphocytes</article-title><source>British Journal of Pharmacology</source><volume>146</volume><fpage>435</fpage><lpage>444</lpage><pub-id pub-id-type="doi">10.1038/sj.bjp.0706322</pub-id><pub-id pub-id-type="pmid">15997228</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scrivens</surname><given-names>M</given-names></name><name><surname>Dickenson</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Functional expression of the P2Y14 receptor in human neutrophils</article-title><source>European Journal of Pharmacology</source><volume>543</volume><fpage>166</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2006.05.037</pub-id><pub-id pub-id-type="pmid">16820147</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Serra</surname><given-names>E</given-names></name><name><surname>Puig</surname><given-names>S</given-names></name><name><surname>Otero</surname><given-names>D</given-names></name><name><surname>Gaona</surname><given-names>A</given-names></name><name><surname>Kruyer</surname><given-names>H</given-names></name><name><surname>Ars</surname><given-names>E</given-names></name><name><surname>Estivill</surname><given-names>X</given-names></name><name><surname>Lázaro</surname><given-names>C</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Confirmation of a double hit model for the Nf1 gene in beningn neurofibromas</article-title><source>The American Journal of Human Genetics</source><volume>61</volume><fpage>512</fpage><lpage>519</lpage><pub-id pub-id-type="doi">10.1086/515504</pub-id><pub-id pub-id-type="pmid">9326316</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Serra</surname><given-names>E</given-names></name><name><surname>Ars</surname><given-names>E</given-names></name><name><surname>Ravella</surname><given-names>A</given-names></name><name><surname>Sánchez</surname><given-names>A</given-names></name><name><surname>Puig</surname><given-names>S</given-names></name><name><surname>Rosenbaum</surname><given-names>T</given-names></name><name><surname>Estivill</surname><given-names>X</given-names></name><name><surname>Lázaro</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Somatic NF1 mutational spectrum in benign neurofibromas: mRNA splice defects are common among point mutations</article-title><source>Human Genetics</source><volume>108</volume><fpage>416</fpage><lpage>429</lpage><pub-id pub-id-type="doi">10.1007/s004390100514</pub-id><pub-id pub-id-type="pmid">11409870</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheela</surname><given-names>S</given-names></name><name><surname>Riccardi</surname><given-names>VM</given-names></name><name><surname>Ratner</surname><given-names>N</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>Angiogenic and invasive properties of neurofibroma Schwann cells</article-title><source>Journal of Cell Biology</source><volume>111</volume><fpage>645</fpage><lpage>653</lpage><pub-id pub-id-type="doi">10.1083/jcb.111.2.645</pub-id><pub-id pub-id-type="pmid">1696266</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sherman</surname><given-names>LS</given-names></name><name><surname>Atit</surname><given-names>R</given-names></name><name><surname>Rosenbaum</surname><given-names>T</given-names></name><name><surname>Cox</surname><given-names>AD</given-names></name><name><surname>Ratner</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Single Cell Ras-GTP Analysis Reveals Altered Ras Activity in a Subpopulation of Neurofibroma Schwann Cells but Not Fibroblasts</article-title><source>The Journal of Biological Chemistry</source><volume>275</volume><fpage>30740</fpage><lpage>30745</lpage><pub-id pub-id-type="doi">10.1074/jbc.M001702200</pub-id><pub-id pub-id-type="pmid">10900196</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simanshu</surname><given-names>DK</given-names></name><name><surname>Nissley</surname><given-names>DV</given-names></name><name><surname>McCormick</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>RAS Proteins and Their Regulators in Human Disease</article-title><source>Cell</source><volume>170</volume><fpage>17</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.06.009</pub-id><pub-id pub-id-type="pmid">28666118</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skelton</surname><given-names>L</given-names></name><name><surname>Cooper</surname><given-names>M</given-names></name><name><surname>Murphy</surname><given-names>M</given-names></name><name><surname>Platt</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Human immature monocyte-derived dendritic cells express the G protein-coupled receptor GPR105 (KIAA0001, P2Y14) and increase intracellular calcium in response to its agonist, uridine diphosphoglucose</article-title><source>Journal of Immunology (Baltimore, Md)</source><volume>171</volume><fpage>1941</fpage><lpage>1949</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.171.4.1941</pub-id><pub-id pub-id-type="pmid">12902497</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stierli</surname><given-names>S</given-names></name><name><surname>Napoli</surname><given-names>I</given-names></name><name><surname>White</surname><given-names>IJ</given-names></name><name><surname>Cattin</surname><given-names>A-L</given-names></name><name><surname>Monteza Cabrejos</surname><given-names>A</given-names></name><name><surname>Garcia Calavia</surname><given-names>N</given-names></name><name><surname>Malong</surname><given-names>L</given-names></name><name><surname>Ribeiro</surname><given-names>S</given-names></name><name><surname>Nihouarn</surname><given-names>J</given-names></name><name><surname>Williams</surname><given-names>R</given-names></name><name><surname>Young</surname><given-names>KM</given-names></name><name><surname>Richardson</surname><given-names>WD</given-names></name><name><surname>Lloyd</surname><given-names>AC</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The regulation of the homeostasis and regeneration of peripheral nerve is distinct from the CNS and independent of a stem cell population</article-title><source>Development (Cambridge, England)</source><volume>145</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1242/dev.170316</pub-id><pub-id pub-id-type="pmid">30413560</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tabata</surname><given-names>MM</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Knight</surname><given-names>P</given-names></name><name><surname>Bakker</surname><given-names>A</given-names></name><name><surname>Sarin</surname><given-names>KY</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Phenotypic heterogeneity of neurofibromatosis type 1 in a large international registry</article-title><source>JCI Insight</source><volume>5</volume><elocation-id>136262</elocation-id><pub-id pub-id-type="doi">10.1172/jci.insight.136262</pub-id><pub-id pub-id-type="pmid">32814709</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tong</surname><given-names>J</given-names></name><name><surname>Hannan</surname><given-names>F</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Bernards</surname><given-names>A</given-names></name><name><surname>Zhong</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Neurofibromin regulates G protein-stimulated adenylyl cyclase activity</article-title><source>Nature Neuroscience</source><volume>5</volume><fpage>95</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1038/nn792</pub-id><pub-id pub-id-type="pmid">11788835</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>JA</given-names></name><name><surname>Bernards</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>A <italic>Drosophila</italic> screen identifies neurofibromatosis-1 genetic modifiers involved in systemic and synaptic growth</article-title><source>Rare Diseases (Austin, Tex.)</source><volume>2</volume><elocation-id>e28341</elocation-id><pub-id pub-id-type="doi">10.4161/rdis.28341</pub-id><pub-id pub-id-type="pmid">25054093</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warrington</surname><given-names>NM</given-names></name><name><surname>Gianino</surname><given-names>SM</given-names></name><name><surname>Jackson</surname><given-names>E</given-names></name><name><surname>Goldhoff</surname><given-names>P</given-names></name><name><surname>Garbow</surname><given-names>JR</given-names></name><name><surname>Piwnica-Worms</surname><given-names>D</given-names></name><name><surname>Gutmann</surname><given-names>DH</given-names></name><name><surname>Rubin</surname><given-names>JB</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1</article-title><source>Cancer Research</source><volume>70</volume><fpage>5717</fpage><lpage>5727</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-3769</pub-id><pub-id pub-id-type="pmid">20551058</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>JP</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Johansson</surname><given-names>G</given-names></name><name><surname>Rizvi</surname><given-names>TA</given-names></name><name><surname>Miller</surname><given-names>SC</given-names></name><name><surname>Geiger</surname><given-names>H</given-names></name><name><surname>Malik</surname><given-names>P</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Mukouyama</surname><given-names>Y</given-names></name><name><surname>Cancelas</surname><given-names>JA</given-names></name><name><surname>Ratner</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Nf1 Mutation Expands an EGFR-Dependent Peripheral Nerve Progenitor that Confers Neurofibroma Tumorigenic Potential</article-title><source>Cell Stem Cell</source><volume>3</volume><fpage>658</fpage><lpage>669</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2008.10.003</pub-id><pub-id pub-id-type="pmid">19041782</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolman</surname><given-names>MA</given-names></name><name><surname>de Groh</surname><given-names>ED</given-names></name><name><surname>McBride</surname><given-names>SM</given-names></name><name><surname>Jongens</surname><given-names>TA</given-names></name><name><surname>Granato</surname><given-names>M</given-names></name><name><surname>Epstein</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Modulation of cAMP and Ras signaling pathways improves distinct behavioral deficits in a zebrafish model of neurofibromatosis type 1</article-title><source>Cell Reports</source><volume>8</volume><fpage>1265</fpage><lpage>1270</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2014.07.054</pub-id><pub-id pub-id-type="pmid">25176649</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Williams</surname><given-names>JP</given-names></name><name><surname>Rizvi</surname><given-names>TA</given-names></name><name><surname>Kordich</surname><given-names>JJ</given-names></name><name><surname>Witte</surname><given-names>D</given-names></name><name><surname>Meijer</surname><given-names>D</given-names></name><name><surname>Stemmer-Rachamimov</surname><given-names>AO</given-names></name><name><surname>Cancelas</surname><given-names>JA</given-names></name><name><surname>Ratner</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Plexiform and Dermal Neurofibromas and Pigmentation Are Caused by Nf1 Loss in Desert Hedgehog-Expressing Cells</article-title><source>Cancer Cell</source><volume>13</volume><fpage>105</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2007.12.027</pub-id><pub-id pub-id-type="pmid">18242511</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Keng</surname><given-names>VW</given-names></name><name><surname>Patmore</surname><given-names>DM</given-names></name><name><surname>Kendall</surname><given-names>JJ</given-names></name><name><surname>Patel</surname><given-names>AV</given-names></name><name><surname>Jousma</surname><given-names>E</given-names></name><name><surname>Jessen</surname><given-names>WJ</given-names></name><name><surname>Choi</surname><given-names>K</given-names></name><name><surname>Tschida</surname><given-names>BR</given-names></name><name><surname>Silverstein</surname><given-names>KAT</given-names></name><name><surname>Fan</surname><given-names>D</given-names></name><name><surname>Schwartz</surname><given-names>EB</given-names></name><name><surname>Fuchs</surname><given-names>JR</given-names></name><name><surname>Zou</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>M-O</given-names></name><name><surname>Dombi</surname><given-names>E</given-names></name><name><surname>Levy</surname><given-names>DE</given-names></name><name><surname>Huang</surname><given-names>G</given-names></name><name><surname>Cancelas</surname><given-names>JA</given-names></name><name><surname>Stemmer-Rachamimov</surname><given-names>AO</given-names></name><name><surname>Spinner</surname><given-names>RJ</given-names></name><name><surname>Largaespada</surname><given-names>DA</given-names></name><name><surname>Ratner</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation</article-title><source>Cell Reports</source><volume>14</volume><fpage>1979</fpage><lpage>1990</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.01.074</pub-id><pub-id pub-id-type="pmid">26904939</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>GF</given-names></name><name><surname>O’Connell</surname><given-names>P</given-names></name><name><surname>Viskochil</surname><given-names>D</given-names></name><name><surname>Cawthon</surname><given-names>R</given-names></name><name><surname>Robertson</surname><given-names>M</given-names></name><name><surname>Culver</surname><given-names>M</given-names></name><name><surname>Dunn</surname><given-names>D</given-names></name><name><surname>Stevens</surname><given-names>J</given-names></name><name><surname>Gesteland</surname><given-names>R</given-names></name><name><surname>White</surname><given-names>R</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>The neurofibromatosis type 1 gene encodes a protein related to GAP</article-title><source>Cell</source><volume>62</volume><fpage>599</fpage><lpage>608</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(90)90024-9</pub-id><pub-id pub-id-type="pmid">2116237</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Morinaga</surname><given-names>H</given-names></name><name><surname>Oh</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Chen</surname><given-names>A</given-names></name><name><surname>Talukdar</surname><given-names>S</given-names></name><name><surname>Lazarowski</surname><given-names>E</given-names></name><name><surname>Olefsky</surname><given-names>JM</given-names></name><name><surname>Kim</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>GPR105 ablation prevents inflammation and improves insulin sensitivity in mice with diet-induced obesity</article-title><source>The Journal of Immunology</source><volume>189</volume><fpage>1992</fpage><lpage>1999</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1103207</pub-id><pub-id pub-id-type="pmid">22778393</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>H</given-names></name><name><surname>Chang</surname><given-names>L</given-names></name><name><surname>Patel</surname><given-names>N</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Lowe</surname><given-names>L</given-names></name><name><surname>Burns</surname><given-names>DK</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Induction of abnormal proliferation by nonmyelinating schwann cells triggers neurofibroma formation</article-title><source>Cancer Cell</source><volume>13</volume><fpage>117</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2008.01.002</pub-id><pub-id pub-id-type="pmid">18242512</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Ghosh</surname><given-names>P</given-names></name><name><surname>Charnay</surname><given-names>P</given-names></name><name><surname>Burns</surname><given-names>DK</given-names></name><name><surname>Parada</surname><given-names>LF</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Neurofibromas in NF1: Schwann cell origin and role of tumor environment</article-title><source>Science (New York, N.Y.)</source><volume>296</volume><fpage>920</fpage><lpage>922</lpage><pub-id pub-id-type="doi">10.1126/science.1068452</pub-id><pub-id pub-id-type="pmid">11988578</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.73511.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hahn</surname><given-names>William C</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02jzgtq86</institution-id><institution>Dana-Farber Cancer Institute</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group></front-stub><body><p>This study explores a role for the purinergic receptor P2RY14 and cAMP signaling in Schwann cell precursor self-renewal and neurofibroma development. Importantly, the authors show that genetic and chemical inhibition of P2RY14 inhibits Schwann cell precursor self-renewal in vitro and suppresses neurofibroma development in vivo. The authors also report that these effects are mediated by an increase in cAMP signaling.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.73511.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Hahn</surname><given-names>William C</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02jzgtq86</institution-id><institution>Dana-Farber Cancer Institute</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="box1"><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>[Editors’ note: the authors submitted for reconsideration following the decision after peer review. What follows is the decision letter after the first round of review.]</p><p>Thank you for submitting the paper &quot;Purinergic receptor P2RY14 cAMP signaling regulates EGFR-driven Schwann cell precursor self-renewal and nerve tumor initiation in neurofibromatosis&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 2 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and a Senior Editor. The reviewers have opted to remain anonymous.</p><p>We are sorry to say that, after consultation with the reviewers, we have decided that this work will not be considered further for publication by <italic>eLife</italic>.</p><p>Both reviewers recognized the significant work presented in this manuscript and felt that the connection between P2RY14 loss, cAMP pathway activation, SCP self-renewal and neurofibroma development is well supported. However, the major observation describing the relationship between P2RY14 and EGFR signaling was supported by experiments performed in a number of different cell systems without adequate demonstration that the systems provide insight into the same biology. The connections between human and murine cells was also not always consistent. For these reasons, the reviewers remained skeptical that this relationship is as described in the manuscript. Since considerable work would be necessary to perform a significant number of new experiments in different systems, we are returning this manuscript to you so that you might consider other options for the work.</p><p><italic>Reviewer #1:</italic></p><p>The NF1 tumor suppressor regulates the Ras pathway but it has also been implicated in cAMP signaling. In this study the authors first sought to identify receptor(s), impinging on the cAMP pathway, that might be involved in neurofibroma development. Notably, they found that the purinergic receptor P2RY14 is enriched in Schwann cell precursors, the cell of origin for neurofibromas. They then demonstrate that (1) genetic and chemical suppression of P2RY14 results in enhanced cAMP signaling, (2) this increased cAMP signaling inhibits the enhanced self-renewal of NF1-deficient Schwann cell precursors, and (3) genetic P2RY14 ablation suppresses neurofibroma initiation in a GEMM model.</p><p>Strengths: A major strength of this manuscript are the impressive in vivo phenotypes. Specifically, the authors convincingly demonstrate that genetic P2RY14 ablation reduces neurofibroma development in a well-characterized mouse (GEMM) model. Another strength lies in the in vitro studies examining self-renewal of Schwann cell precursors (SCPs), which suggest that tumor suppression mediated by P2RY14-loss occurs by inhibiting tumor initiation due to an increase in cAMP signaling. Together these findings reveal a new and important pathway that contributes to neurofibroma development. Moreover, this study suggests that P2RY14 may represent a potential therapeutic target in these tumors.</p><p>Weaknesses: Because NF1 regulates the Ras pathway and converges on EGFR signaling in SCPs, the authors also examine whether P2RY14 impinges on these pathways. They do show that P2RY14 inhibition attenuates either AKT, ERK and/or EGFR in various systems (mouse SCPs, human SCPs, and human MPNST cells) in vitro. However, the relative importance of these pathways downstream of P2RY14 is not clear as presented. This is in part because not all 3 events (pERK, pAKT, pEGFR) are evaluated in all settings, and effects appear to be minimal in vivo (and/or not examined). This may be due to the fact that the phenotype appears to be primarily related to SCP self-renewal and tumor initiation, and therefore signaling defects may be difficult to capture in this context.</p><p>While the connection between P2RY14 loss, cAMP pathway activation, SCP self-renewal and neurofibroma development is well supported, the connection between P2RY14 loss and EGFR, pERK, pAKT is less clear in the current version of this manuscript. For example, in immortalized human Schwann cells, P2RY14 suppression attenuates pEGFR and pAKT, but has no effect on pERK. By contrast, only ERK is examined in mouse SCPs and it is only modestly suppressed, whereas both ERK and AKT are both attenuated in MPNSTs. Finally, only pERK is examined in vivo, and it is not convincingly suppressed by P2RY14 loss.</p><p>If the authors wish to claim that P2RY14 loss impacts EGFR signaling, it would be important to measure the same signals in all settings. For example, can they examine pEGFR, pAKT and pERK in the mouse cells used in Figure 2F? If not I would suggest deleting this panel altogether, because it raises doubt about later figures.</p><p>Similarly, can the authors also examine pEGFR and pAKT in vivo in 5I? (Although, unfortunately the pERK is not very convincing). Ultimately, if the authors really believe that tumor suppression is due to direct suppression of EGFR activation/phosphorylation, pEGFR should be inhibited in all settings (while defects in ERK and AKT may vary). Of course, it is possible that signaling defects might not be easily captured in vivo, especially if the biological defect is in tumor initiation and therefore may not be present in many cells in established tumors. If that is the case then it may be better not to show the minimal effects on pERK at all in vivo in panel 5I, especially given the very dramatic effects on PKA shown in panel 5H.</p><p>The authors claim that P2RY14 and EGFR physically interact, however additional negative controls are required to support this conclusion. If they wish to claim that there is a physical association, they must use a GFP-expressing control and then IP with anti-GFP rather than performing a mock immunoprecipitation (given the sticky nature of GFP). Nevertheless, proof of a direct interaction is not necessary for the concept of feedback interference with EGFR signaling (depending on supportive signaling data described above).</p><p>Overall, I would suggest that the authors either (1) strengthen the P2Y14-EGFR connection, (2) only include the experiments shown in Figure 3 and temper conclusions suggesting the involvement of EGFR suppression in this phenotype (eg &quot;suppression of EGFR signaling may also contribute&quot;), or (3) remove the discussion of cross-talk suppression altogether.</p><p><italic>Reviewer #2:</italic></p><p>Using patient-derived neurofibroma samples, the authors first showed that compared to p75+EGFR- neurofibroma cells, P2RY14 was expressed at higher levels in p75+EGFR+ cells, which was also correlated with higher neurosphere-forming abilities in vitro. Secondly, the authors showed that inhibition of P2RY14 by either a specific inhibitor, PPTN, or shRNAs for P2RY14, inhibited neurosphere-forming activities of Nf1-/- cultured mouse Schwann cell precursor (SCP) cells, but exhibited little effect on Nf1+/+ cultures. Thirdly, the authors showed that immortalized human Schwann cells (iHSCs) without NF1 (NF1-/-) exhibited increased growth advantage compared with NF1+/+ counterparts. Using P2RY14-specific UDP agonist, P2RY14 inhibitor and IBMX (an inhibitor of PDEs), the authors showed that activation versus inhibition of P2RY14 activities are correlated with a decrease versus an increase of cAMP signaling based on pCREB expression. In NF1-/- iHSCs, P2RY14 inhibition reduced phosphorylation of EGFR and shortened the duration of p-AKT signaling. Finally, germline knockout of P2RY14 reduced neurofibroma burden and extended life span of the Dhh-cre driven NF1-associated neurofibroma model. However, treatment of Rolipram, which inhibits PDE4 and blocks degradation of cAMP, increased cAMP and decreased proliferation in neurofibromas, but failed to significantly alter tumor volume in the Dhh-cre driven neurofibroma model. This study presents a lot of data derived from different types of in vitro and in vivo systems, including from both humans and mouse models. However, it is not clear why different in vitro or in vivo models were used to investigate the hypothesis. The conclusions from human and mouse systems regarding the role of P2RY14 in neurofibroma initiation versus progression, are not necessarily consistent with each other. The relationship between P2RY14 and EGFR signaling is not fully established in neurofibroma cells.</p><p>The paper needs to be restructured, focuses on one or few points of the paper and perform additional experiments to justify the conclusions.</p><p>It would strengthen the manuscript if the following questions are addressed.</p><p>1. Studies using patient-derived neurofibroma cells suggest a role of P2RY14 in promoting neurofibroma growth (Figure 1). However, mouse studies using Rolipram treatment have little effect on neurofibroma volume, despite increasing cAMP signaling (Figure 6). How can these human and mouse studies be reconciled?</p><p>2. It is not clear why inhibition of P2RY14 in cultured mouse SCP cells only inhibits the neurosphere-forming abilities of NF1-/- cells, but not NF1+/+ cells, though cAMP signaling was similarly increased (Figure 2G). Do these data argue against the notion that P2PY14 signals through the cAMP signaling pathway.</p><p>3. In Figure 3, the relationship between P2RY14, cAMP and EGFR pathways is at best correlative, but lacks direct evidence to establish a causal relationship. Further, it is not clear why malignant peripheral nerve sheath tumor cell lines were used in these studies (Figure 3E-G), which may not be relevant to neurofibroma cells.</p><p>4. The observation that germline P2PY14 knockout inhibits neurofibroma formation in the Dhh-cre driven mouse model is interesting (Figure 4 and 5). However, it is not clear how this inhibition is related to cAMP and/or EGFR signaling pathways in vivo?</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.73511.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><p>[Editors’ note: The authors appealed the original decision. What follows is the authors’ response to the first round of review.]</p><disp-quote content-type="editor-comment"><p>Reviewer #1:</p><p>The NF1 tumor suppressor regulates the Ras pathway but it has also been implicated in cAMP signaling. In this study the authors first sought to identify receptor(s), impinging on the cAMP pathway, that might be involved in neurofibroma development. Notably, they found that the purinergic receptor P2RY14 is enriched in Schwann cell precursors, the cell of origin for neurofibromas. They then demonstrate that (1) genetic and chemical suppression of P2RY14 results in enhanced cAMP signaling, (2) this increased cAMP signaling inhibits the enhanced self-renewal of NF1-deficient Schwann cell precursors, and (3) genetic P2RY14 ablation suppresses neurofibroma initiation in a GEMM model.</p><p>Strengths: A major strength of this manuscript are the impressive in vivo phenotypes. Specifically, the authors convincingly demonstrate that genetic P2RY14 ablation reduces neurofibroma development in a well-characterized mouse (GEMM) model. Another strength lies in the in vitro studies examining self-renewal of Schwann cell precursors (SCPs), which suggest that tumor suppression mediated by P2RY14-loss occurs by inhibiting tumor initiation due to an increase in cAMP signaling. Together these findings reveal a new and important pathway that contributes to neurofibroma development. Moreover, this study suggests that P2RY14 may represent a potential therapeutic target in these tumors.</p><p>Weaknesses: Because NF1 regulates the Ras pathway and converges on EGFR signaling in SCPs, the authors also examine whether P2RY14 impinges on these pathways. They do show that P2RY14 inhibition attenuates either AKT, ERK and/or EGFR in various systems (mouse SCPs, human SCPs, and human MPNST cells) in vitro. However, the relative importance of these pathways downstream of P2RY14 is not clear as presented. This is in part because not all 3 events (pERK, pAKT, pEGFR) are evaluated in all settings, and effects appear to be minimal in vivo (and/or not examined). This may be due to the fact that the phenotype appears to be primarily related to SCP self-renewal and tumor initiation, and therefore signaling defects may be difficult to capture in this context.</p><p>While the connection between P2RY14 loss, cAMP pathway activation, SCP self-renewal and neurofibroma development is well supported, the connection between P2RY14 loss and EGFR, pERK, pAKT is less clear in the current version of this manuscript. For example, in immortalized human Schwann cells, P2RY14 suppression attenuates pEGFR and pAKT, but has no effect on pERK. By contrast, only ERK is examined in mouse SCPs and it is only modestly suppressed, whereas both ERK and AKT are both attenuated in MPNSTs. Finally, only pERK is examined in vivo, and it is not convincingly suppressed by P2RY14 loss.</p></disp-quote><p>All removed.</p><disp-quote content-type="editor-comment"><p>If the authors wish to claim that P2RY14 loss impacts EGFR signaling, it would be important to measure the same signals in all settings. For example, can they examine pEGFR, pAKT and pERK in the mouse cells used in Figure 2F? If not I would suggest deleting this panel altogether, because it raises doubt about later figures.</p></disp-quote><p>All removed.</p><disp-quote content-type="editor-comment"><p>Similarly, can the authors also examine pEGFR and pAKT in vivo in 5I? (Although, unfortunately the pERK is not very convincing). Ultimately, if the authors really believe that tumor suppression is due to direct suppression of EGFR activation/phosphorylation, pEGFR should be inhibited in all settings (while defects in ERK and AKT may vary). Of course, it is possible that signaling defects might not be easily captured in vivo, especially if the biological defect is in tumor initiation and therefore may not be present in many cells in established tumors. If that is the case then it may be better not to show the minimal effects on pERK at all in vivo in panel 5I, especially given the very dramatic effects on PKA shown in panel 5H.</p></disp-quote><p>Done; Figure 5I was deleted.</p><disp-quote content-type="editor-comment"><p>The authors claim that P2RY14 and EGFR physically interact, however additional negative controls are required to support this conclusion. If they wish to claim that there is a physical association, they must use a GFP-expressing control and then IP with anti-GFP rather than performing a mock immunoprecipitation (given the sticky nature of GFP). Nevertheless, proof of a direct interaction is not necessary for the concept of feedback interference with EGFR signaling (depending on supportive signaling data described above).</p></disp-quote><p>We agree and removed this data.</p><disp-quote content-type="editor-comment"><p>Overall, I would suggest that the authors either (1) strengthen the P2Y14-EGFR connection, (2) only include the experiments shown in Figure 3 and temper conclusions suggesting the involvement of EGFR suppression in this phenotype (eg &quot;suppression of EGFR signaling may also contribute&quot;), or (3) remove the discussion of cross-talk suppression altogether.</p></disp-quote><p>We agree. We removed all discussion of cross-talk and will consider a separate, strengthened manuscript on cross-talk.</p><disp-quote content-type="editor-comment"><p>Reviewer #2:</p><p>Using patient-derived neurofibroma samples, the authors first showed that compared to p75+EGFR- neurofibroma cells, P2RY14 was expressed at higher levels in p75+EGFR+ cells, which was also correlated with higher neurosphere-forming abilities in vitro. Secondly, the authors showed that inhibition of P2RY14 by either a specific inhibitor, PPTN, or shRNAs for P2RY14, inhibited neurosphere-forming activities of Nf1-/- cultured mouse Schwann cell precursor (SCP) cells, but exhibited little effect on Nf1+/+ cultures. Thirdly, the authors showed that immortalized human Schwann cells (iHSCs) without NF1 (NF1-/-) exhibited increased growth advantage compared with NF1+/+ counterparts. Using P2RY14-specific UDP agonist, P2RY14 inhibitor and IBMX (an inhibitor of PDEs), the authors showed that activation versus inhibition of P2RY14 activities are correlated with a decrease versus an increase of cAMP signaling based on pCREB expression. In NF1-/- iHSCs, P2RY14 inhibition reduced phosphorylation of EGFR and shortened the duration of p-AKT signaling. Finally, germline knockout of P2RY14 reduced neurofibroma burden and extended life span of the Dhh-cre driven NF1-associated neurofibroma model. However, treatment of Rolipram, which inhibits PDE4 and blocks degradation of cAMP, increased cAMP and decreased proliferation in neurofibromas, but failed to significantly alter tumor volume in the Dhh-cre driven neurofibroma model. This study presents a lot of data derived from different types of in vitro and in vivo systems, including from both humans and mouse models. However, it is not clear why different in vitro or in vivo models were used to investigate the hypothesis. The conclusions from human and mouse systems regarding the role of P2RY14 in neurofibroma initiation versus progression, are not necessarily consistent with each other. The relationship between P2RY14 and EGFR signaling is not fully established in neurofibroma cells.</p><p>The paper needs to be restructured, focuses on one or few points of the paper and perform additional experiments to justify the conclusions.</p></disp-quote><p>We agree completely and extensively revised the manuscript.</p><disp-quote content-type="editor-comment"><p>It would strengthen the manuscript if the following questions are addressed.</p><p>1. Studies using patient-derived neurofibroma cells suggest a role of P2RY14 in promoting neurofibroma growth (Figure 1). However, mouse studies using Rolipram treatment have little effect on neurofibroma volume, despite increasing cAMP signaling (Figure 6). How can these human and mouse studies be reconciled?</p></disp-quote><p>We removed the Rolipram volume data because numbers of treated mice were insufficient for statistical analysis. Experiments would require a year to generate and treat the 10-17 additional mice for accurate volumetric analysis. We replaced this with a statement that more work will be needed to define long term effects. In addition, to strengthen our argument we added a new study using a direct and specific P2RY14 antagonist, which confirms and extends the Rolipram data showing effects on cell proliferation.</p><disp-quote content-type="editor-comment"><p>2. It is not clear why inhibition of P2RY14 in cultured mouse SCP cells only inhibits the neurosphere-forming abilities of NF1-/- cells, but not NF1+/+ cells, though cAMP signaling was similarly increased (Figure 2G). Do these data argue against the notion that P2PY14 signals through the cAMP signaling pathway.</p></disp-quote><p>Data in Figure 2 shows that PPTN or shRNA targeting P2RY14 have effects on both wild type and on Nf1 mutant SCP spheres. The key result is that effects are significantly more in the mutant versus wild type cells. This differential effect is consistent with de-regulated cell signaling in Nf1 mutant cells. For example, both WT and mutant cells use P-ERK, yet MAPK inhibition shows more effect on mutant versus wild type cells in vivo. We clarified this in the text in lines 182-184.</p><disp-quote content-type="editor-comment"><p>3. In Figure 3, the relationship between P2RY14, cAMP and EGFR pathways is at best correlative, but lacks direct evidence to establish a causal relationship. Further, it is not clear why malignant peripheral nerve sheath tumor cell lines were used in these studies (Figure 3E-G), which may not be relevant to neurofibroma cells.</p></disp-quote><p>We agree and so removed this data.</p><disp-quote content-type="editor-comment"><p>4. The observation that germline P2PY14 knockout inhibits neurofibroma formation in the Dhh-cre driven mouse model is interesting (Figure 4 and 5). However, it is not clear how this inhibition is related to cAMP and/or EGFR signaling pathways in vivo?</p></disp-quote><p>Unfortunately, we cannot directly address this question in vivo. However, given that blockade of either EGFR or P2RY14 in vivo and in SCP in vitro reduces tumor initiation provides strong correlation, but does not demonstrate causality for the in vivo effect, which is provided by the in vitro experiments. For this reason, we add data to show in vivo that raising cAMP levels by rolipram or by P2RY14 antagonism similarly affect neurofibroma cell proliferation.</p></body></sub-article></article>